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A B S T R A C T
Background
Primary biliary cholangitis (previously primary biliary cirrhosis) is a chronic liver disease caused by the destruction of small intra-hepatic
bile ducts resulting in stasis of bile (cholestasis), liver fibrosis, and liver cirrhosis. The optimal pharmacological treatment of primary
biliary cholangitis remains uncertain.
Objectives
To assess the comparative benefits and harms of different pharmacological interventions in the treatment of primary biliary cholangitis
through a network meta-analysis and to generate rankings of the available pharmacological interventions according to their safety and
efficacy.However, it was not possible to assess whether the potential effectmodifiers were similar across different comparisons. Therefore,
we did not perform the network meta-analysis, and instead, assessed the comparative benefits and harms of different interventions
using standard Cochrane methodology.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2), MEDLINE, Embase, Science Citation
Index Expanded, World Health Organization International Clinical Trials Registry Platform, and randomised controlled trials registers
to February 2017 to identify randomised clinical trials on pharmacological interventions for primary biliary cholangitis.
Selection criteria
We included only randomised clinical trials (irrespective of language, blinding, or publication status) in participants with primary
biliary cholangitis. We excluded trials which included participants who had previously undergone liver transplantation. We considered
any of the various pharmacological interventions compared with each other or with placebo or no intervention.
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Data collection and analysis
We used standard methodological procedures expected by Cochrane. We calculated the odds ratio (OR) and rate ratio with 95%
confidence intervals (CI) using both fixed-effect and random-effectsmodels based on available-participant analysis with ReviewManager
5. We assessed risk of bias according to Cochrane, controlled risk of random errors with Trial Sequential Analysis, and assessed the
quality of the evidence using GRADE.
Main results
We identified 74 trials including 5902 participants that met the inclusion criteria of this review. A total of 46 trials (4274 participants)
provided information for one or more outcomes. All the trials were at high risk of bias in one or more domains. Overall, all the evidence
was low or very low quality. The proportion of participants with symptoms varied from 19.9% to 100% in the trials that reported this
information. The proportion of participants who were antimitochondrial antibody (AMA) positive ranged from 80.8% to 100% in
the trials that reported this information. It appeared that most trials included participants who had not received previous treatments or
included participants regardless of the previous treatments received. The follow-up in the trials ranged from 1 to 96 months.
The proportion of people with mortality (maximal follow-up) was higher in the methotrexate group versus the no intervention group
(OR 8.83, 95% CI 1.01 to 76.96; 60 participants; 1 trial; low quality evidence). The proportion of people with mortality (maximal
follow-up) was lower in the azathioprine group versus the no intervention group (OR 0.56, 95% CI 0.32 to 0.98; 224 participants;
2 trials; I2 = 0%; low quality evidence). However, it has to be noted that a large proportion of participants (25%) was excluded from
the trial that contributed most participants to this analysis and the results were not reliable. There was no evidence of a difference in
any of the remaining comparisons. The proportion of people with serious adverse events was higher in the D-penicillamine versus no
intervention group (OR 28.77, 95% CI 1.57 to 526.67; 52 participants; 1 trial; low quality evidence). The proportion of people with
serious adverse events was higher in the obeticholic acid plus ursodeoxycholic acid (UDCA) group versus the UDCA group (OR 3.58,
95% CI 1.02 to 12.51; 216 participants; 1 trial; low quality evidence). There was no evidence of a difference in any of the remaining
comparisons for serious adverse events (proportion) or serious adverse events (number of events). None of the trials reported health-
related quality of life at any time point.
Funding: nine trials had no special funding or were funded by hospital or charities; 31 trials were funded by pharmaceutical companies;
and 34 trials provided no information on source of funding.
Authors’ conclusions
Based on very low quality evidence, there is currently no evidence that any intervention is beneficial for primary biliary cholangitis.
However, the follow-up periods in the trials were short and there is significant uncertainty in this issue. Further well-designed randomised
clinical trials are necessary. Future randomised clinical trials ought to be adequately powered; performed in people who are generally
seen in the clinic rather than in highly selected participants; employ blinding; avoid post-randomisation dropouts or planned cross-
overs; should have sufficient follow-up period (e.g. five or 10 years or more); and use clinically important outcomes such as mortality,
health-related quality of life, cirrhosis, decompensated cirrhosis, and liver transplantation. Alternatively, very large groups of participants
should be randomised to facilitate shorter trial duration.
P L A I N L A N G U A G E S U M M A R Y
Medical treatment of primary biliary cholangitis
Background
Primary biliary cholangitis (previously called primary biliary cirrhosis) is a chronic liver disease caused by the destruction of small bile
ducts within the liver (tubes that carry the bile produced by the liver) resulting in stagnation of bile (cholestasis) and liver damage and
replacement of liver cells with scar tissue (liver cirrhosis). The best way to treat people with primary biliary cholangitis is unclear. We
sought to resolve this issue by searching for existing trials on the topic. We included all randomised clinical trials (clinical studies where
people are randomly put into one of two or more intervention groups) reported to February 2017. We included only trials in which
participants with primary biliary cholangitis had not undergone liver transplantation previously. Apart from using standard Cochrane
methods which allow comparison of only two treatments at a time (direct comparison), we planned to use an advanced method which
allows comparison of the many different treatments that are individually compared in the trials (network meta-analysis). However,
because of the nature of the information available, we could not determine whether the network meta-analysis results were reliable.
Therefore, we used standard Cochrane methodology.
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Study characteristics
We identified 74 randomised clinical trials (5902 participants). Of these, 46 randomised clinical trials (4274 participants) provided
information for one or more measures (outcomes). The trials included people with primary biliary cholangitis with and without
symptoms; with and without antimitochondrial antibody (AMA) (an indicator of primary biliary cholangitis) regardless of whether
they received previous treatments. The average follow-up period in the trials ranged from one month to eight years in the trials that
reported this information.
Funding: nine trials receive no additional funding or were funded by parties with no vested interest in the results. Thirty-one trials were
partially or fully funded by the pharmaceutical companies that would benefit based on the results of the trial. The source of funding
was not available from the remaining trials.
Quality of evidence
The overall quality of evidence was very low and all the trials were at high risk of bias, which means that there is possibility of making
wrong conclusions overestimating benefits or underestimating harms of one treatment or the other because of the way that the trials
were conducted.
Key results
There was no reliable evidence of decrease in the deaths between any of the interventions versus no intervention. There was no evidence
of decrease in serious complications or complications of any severity between any of the treatments and no treatment. None of the
trials reported health-related quality of life (a measure of a person’s satisfaction with their life and health) at any time point.
Overall, there is currently no evidence of benefit of any intervention in primary biliary cholangitis. There is significant uncertainty in
this issue and further high-quality randomised clinical trials are required.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
UDCA versus no intervention for primary biliary cholangitis
Patient or population: people with primary biliary cholangit is
Settings: secondary or tert iary care
Intervention: UDCA
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention UDCA
M ortality at maximal fol-
low-up
Follow-up: 12 to 89 months
208 per 1000 206 per 1000
(136 to 301)
OR 0.99
(0.60 to 1.64)
734
(6 trials)
⊕©©©
Very low1,2
Serious adverse events
(proportion)
Follow-up: 12 to 41 months
There were no events in either group 380
(3 trials)
⊕©©©
Very low1,2,3
Serious adverse events
(number of events)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group proport ion across all the trials. The corresponding risk (and its 95% conf idence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io; UDCA: ursodeoxycholic acid.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias in the trial(s) was high (downgraded by two levels).
2 Sample sizes were small and 95% conf idence intervals overlapped clinically signif icant and clinically insignif icant or no
ef fect (downgraded by two levels).
3 There was moderate heterogeneity (downgraded by one level).
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B A C K G R O U N D
Description of the condition
Primary biliary cholangitis (previously named primary biliary cir-
rhosis) is a chronic liver disease caused by the destruction of small
intrahepatic bile ducts resulting in stasis of bile (cholestasis), liver
fibrosis, and liver cirrhosis (NCBI 2014). There is global varia-
tion in the incidence and prevalence of primary biliary cholangitis
with annual incidence varying from 1.6 to 3.2 per 100,000 people
and prevalence varying from 5 to 38 per 100,000 people, with a
trend of increasing incidence and prevalence in many countries
(Metcalf 1997; Boberg 1998; Kim 2000; Sood 2004; Lazaridis
2007; Pla 2007; Rautiainen 2007; Myers 2009; Baldursdottir
2012; Boonstra 2014). It is more common in women, particularly
aged 25 to 40 years (Metcalf 1997; Kim 2000; Gershwin 2005;
Pla 2007; Myers 2009; Baldursdottir 2012). The mean age at di-
agnosis is 40 to 60 years (Kim 2000; Parikh-Patel 2001; Gershwin
2005; Myers 2009; Baldursdottir 2012).
The aetiology of primary biliary cholangitis is unclear. The as-
sociations with primary biliary cholangitis include family history
of primary biliary cholangitis, Sjögren’s syndrome (autoimmune
disease characterised by dry mouth and dry eyes), systemic lu-
pus erythematosus (autoimmune connective tissue disorder), au-
toimmune thyroid disease, multiple sclerosis (autoimmune disor-
der of the central nervous system), scleroderma (autoimmune dis-
ease affecting the skin and internal organs), polymyositis (chronic
inflammation of the muscles, possibly an autoimmune disease),
history of cigarette smoking, history of hair dye use, and uri-
nary tract infections (Parikh-Patel 2001;Gershwin2005; Lazaridis
2007; Prince 2010; Lammert 2013). People with primary biliary
cholangitis have other coexisting autoimmune disorders such as
rheumatoid arthritis, systemic lupus erythematosus, autoimmune
thyroid disease, multiple sclerosis, scleroderma, and polymyosi-
tis (Parikh-Patel 2001; Gershwin 2005; Prince 2010; Lammert
2013). Although the strong association between personal and fam-
ily history of autoimmune diseases suggests that primary biliary
cholangitis may have an autoimmune aetiology, the clustering of
primary biliary cholangitis in certain areas and associations be-
tween primary biliary cholangitis and hair dye use, past smoking,
and history of urinary tract infections have prompted people to
consider environmental factors such as toxins and infections as
possible aetiologies or triggering factors for primary biliary cholan-
gitis (Leung 2005; Dronamraju 2010; Prince 2010; Selmi 2010).
A significant proportion of people with primary biliary cholangitis
are asymptomatic at the time of diagnosis (up to about 60% in
some studies (Pla 2007)). Itching and fatigue are the most com-
mon symptoms (Pla 2007; Myers 2009). Other ways of clinical
presentation include Raynaud’s syndrome (bluish discolouration
of the fingers and toes due to vasospasm in response to cold or
emotional stress); features of portal hypertension; osteoporosis;
high cholesterol (particularly high ratio of high-density lipoprotein
cholesterol (which is considered protective for the heart) to low-
density lipoprotein cholesterol); and rarely deficiencies of vitamin
A, vitamin D, vitamin E, and vitamin K (Kim 2000; Gershwin
2005; Pla 2007;Myers 2009; Baldursdottir 2012). Approximately
3% to 8% of people require liver transplantation in about five to
six years from diagnosis (Kim 2000; Lindor 2009; Myers 2009;
Baldursdottir 2012). Approximately 3% to 4% of people with pri-
mary biliary cholangitis die every year, usually because of liver-
related causes such as decompensated liver disease or hepatocellu-
lar carcinoma (Rautiainen 2007; Myers 2009). Overall, approxi-
mately 21%to50%of people are dead in about 10 to 11 years from
diagnosis (Kim 2000; Rautiainen 2007; Myers 2009; Floreani
2011; Baldursdottir 2012).
The diagnosis of primary biliary cholangitis ismade in the presence
of any two of the following three criteria (Lindor 2009).
• Elevation of alkaline phosphatases.
• Presence of antimitochondrial antibody (AMA).
• Liver biopsy demonstrating non-suppurative destructive
cholangitis and destruction of interlobular bile ducts.
Some variations of primary biliary cholangitis are AMA-negative
primary biliary cholangitis that requires liver biopsy for establish-
ing the diagnosis and the primary biliary cholangitis - autoim-
mune hepatitis overlap syndrome (Lindor 2009). However, there
is currently no strong evidence that the course of the disease is
different between the classic primary biliary cholangitis and these
variants (Lindor 2009).
Description of the intervention
Various pharmacological interventions have been tried to treat
people with primary biliary cholangitis. These include bile acids
such as ursodeoxycholic acid (UDCA) (Kaplan 2004; Combes
2005; Rautiainen 2005; Rudic 2012a); fibrates such as bezafi-
brate (Kurihara 2000; Rudic 2012b); immunosuppressants or
immunomodulators such as glucocorticosteroids (Prince 2005;
Rautiainen 2005), colchicine (Almasio 2000;Gong2004a;Kaplan
2004), methotrexate (Kaplan 2004; Combes 2005; Giljaca 2010),
azathioprine (Gong 2007a), ciclosporin (Gong 2007b), chlo-
rambucil (Li Wei 2012), mycophenolate mofetil (Jones 1999;
Talwalkar 2005), and thalidomide (McCormick 1994); and cop-
per-chelating agents such as D-penicillamine (Gong 2004b) and
tetrathiomolybdate (Askari 2010). Several other interventions
such as bisphosphonates and hormonal replacement to prevent
or treat osteoporosis (Ormarsdottir 2004; Rudic 2011a; Rudic
2011b; Guanabens 2013); antidepressants such as fluoxetine and
fluvoxamine to overcome fatigue (Ter Borg 2004;Talwalkar 2006);
cholesterol-lowering agents such as simvastatin to decrease the high
cholesterol (Cash 2013); and cholestyramine, rifampicin, and S-
adenosyl methionine for pruritus (Bergasa 2000) have been evalu-
ated for control of various symptoms. Liver transplantation is per-
formed in some people with decompensated liver disease due to
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primary biliary cholangitis (Kim 2000; Lindor 2009;Myers 2009;
Baldursdottir 2012).
How the intervention might work
Certain bile acids are protective while other bile acids are harm-
ful to hepatocytes (liver cells), cholangiocytes (cells that line the
bile duct), and gastrointestinal cells lining the oesophagus and
stomach (Perez 2009). Bile acids such as UDCA may protect
the cholangiocytes from the damage caused by hydrophobic bile
acids by decreasing the oxidative stress (by direct antioxidant ef-
fect or an increase in antioxidant defences) (Paumgartner 2002;
Perez 2009). Bile acids also stimulate the secretion of bile acids
from hepatocytes, thereby decreasing their stasis and the result-
ing damage to the cells and inhibit apoptosis (programmed cell
death) (Paumgartner 2002; Perez 2009). Fibrates inactivate hy-
drophobic bile acids and, therefore, decrease the damage to the
cells (Kurihara 2000). Since primary biliary cholangitis is consid-
ered an autoimmune disorder, altering the immunity and inflam-
matory response using glucocorticoids and other immunosuppres-
sants may decrease the damage resulting from the inflammatory
response. D-Penicillamine and tetrathiomolybdate might remove
the excess copper, thereby protecting the cells from the damage
caused by copper accumulation. They also have antifibrotic prop-
erties (Song 2008). In this Cochrane Review, we included only
pharmacological interventions aimed at controlling the liver dis-
ease (i.e. we excluded symptomatic treatments, lifestyle modifica-
tions, and liver transplantation).
Why it is important to do this review
The optimal pharmacological treatment of primary biliary cholan-
gitis is unknown.Currently, both the EuropeanAssociation for the
Study of the Liver (EASL) and American Association for the Study
of Liver Diseases (AASLD) recommend UDCA for the manage-
ment of primary biliary cholangitis (EASL 2009; Lindor 2009).
However, one Cochrane Review that compared UDCA versus
placebo or no intervention reported that there was no survival or
symptomatic benefit for UDCA (Rudic 2012a). Therefore, there
is clearly a discordance between the evidence and guideline rec-
ommendation. Network meta-analysis allows combination of the
direct evidence and indirect evidence, and allows ranking of differ-
ent interventions in terms of the different outcomes (Salanti 2011;
Salanti 2012). There has been no Cochrane Review on the differ-
ent pharmacological interventions for primary biliary cholangitis.
This systematic review and attempted network meta-analysis pro-
vides the best level of evidence for the role of different interven-
tions used in the treatment of people with primary biliary cholan-
gitis.
O B J E C T I V E S
To assess the comparative benefits and harms of different pharma-
cological interventions in the treatment of primary biliary cholan-
gitis through a network meta-analysis and to generate rankings
of the available pharmacological interventions according to their
safety and efficacy. However, it was not possible to assess whether
the potential effect modifiers were similar across different com-
parisons. Therefore, we did not perform the network meta-anal-
ysis, and, instead, assessed the comparative benefits and harms of
different interventions using standard Cochrane methodology.
When more trials become available with adequate description of
potential effect modifiers, we will attempt to conduct network
meta-analysis to generate rankings of the available interventions
according to their safety and efficacy. This is why we retained the
planned methodology for network meta-analysis in our Appendix
1. Once data appear allowing for the conduct of network meta-
analysis, this Appendix 1 will be moved back into the Methods
section.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered randomised clinical trials only for this network
meta-analysis, irrespective of the language, publication status, or
date of publication. We excluded studies of other design because
of the risk of bias in such studies. We are all aware that such
exclusions make us focus much more on potential benefits and
not fully assess the risks of serious adverse events as well as risks of
adverse events.
Types of participants
We included randomised clinical trials with participants with pri-
mary biliary cholangitis irrespective of the method of diagnosis of
the disease or the presence of symptoms. We excluded randomised
clinical trials in which participants had undergone liver transplan-
tation previously.
Types of interventions
Any of the following pharmacological interventions that are pos-
sible treatments used either alone or in combination for primary
biliary cholangitis and can be compared with each other or with
placebo or no intervention.
The interventions that we considered were:
• UDCA;
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• obeticholic acid;
• bezafibrate;
• glucocorticosteroids;
• colchicine;
• methotrexate;
• azathioprine;
• ciclosporin;
• chlorambucil;
• mycophenolate mofetil;
• thalidomide;
• D-penicillamine;
• tetrathiomolybdate.
The above list was not exhaustive. If we identified pharmacological
interventions that we were not aware of, we considered them as
eligible and included them in the review if theywere used primarily
for the treatment of primary biliary cholangitis.
Types of outcome measures
We assessed the comparative benefits and harms of available phar-
macological interventions aimed at treating people with primary
biliary cholangitis for the following outcomes.
Primary outcomes
• Mortality at maximal follow-up.
• Mortality:
◦ short-term mortality (up to one year);
◦ medium-term mortality (one to five years).
• Adverse events (within three months after cessation of
treatment). Depending on the availability of data, we attempted
to classify adverse events as serious or non-serious. We defined a
non-serious adverse event as any untoward medical occurrence
not necessarily having a causal relationship with the treatment
but resulting in a dose reduction or discontinuation of treatment
(any time after commencement of treatment) (ICH-GCP 1997).
We defined a serious adverse event as any event that would
increase mortality; was life threatening; required hospitalisation;
resulted in persistent or significant disability; was a congenital
anomaly/birth defect; or any important medical event that might
jeopardise the person or require intervention to prevent it. We
used the definition used by study authors for non-serious and
serious adverse events:
◦ proportion of participants with serious adverse events;
◦ number of serious adverse events;
◦ proportion of participants with any type of adverse
event;
◦ number of any type of adverse event.
• Health-related quality of life as defined in the included
trials using a validated scale such as EQ-5D or 36-item Short
Form (SF-36) (EuroQol 2014; Ware 2014):
◦ short-term (up to one year);
◦ medium-term (one to five years);
◦ long-term (beyond five years).
We considered long-term quality of life more important than
short-term or medium-term quality of life, although short-term
and medium-term quality of life are also important primary out-
comes.
Secondary outcomes
• Liver transplantation (maximal follow-up):
◦ proportion of participants with liver transplantation;
◦ time to liver transplantation.
• Decompensated liver disease (maximal follow-up):
◦ proportion of participants with decompensated liver
disease;
◦ time to liver decompensation.
• Cirrhosis (maximal follow-up):
◦ proportion of participants with cirrhosis;
◦ time to cirrhosis.
• Hepatocellular carcinoma (maximal follow-up).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Embase, and Science Citation Index
Expanded (Royle 2003) from inception to 27 February 2017 for
randomised clinical trials comparing two or more of the above
interventions without applying any language restrictions. We
searched for all possible comparisons formed by the interventions
of interest. To identify further ongoing or completed trials, we also
searched the World Health Organization International Clinical
Trials Registry Platform Search Portal (apps.who.int/trialsearch/),
which searches various trial registers, including ISRCTN and
ClinicalTrials.gov. Appendix 2 shows the search strategies we used.
Searching other resources
We searched the references of the identified trials and existing
Cochrane Reviews on primary biliary cholangitis to identify ad-
ditional trials for inclusion.
Data collection and analysis
Selection of studies
Two review authors (KG and FS) independently identified the tri-
als for inclusion by screening the titles and abstracts. We sought
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full-text articles for any references that at least one of the review au-
thors identified for potential inclusion. We selected trials for inclu-
sion based on the full-text articles. We listed the excluded full-text
references with reasons for their exclusion in the Characteristics of
excluded studies table. We have also listed any ongoing trials iden-
tified primarily through the search of the clinical trial registers for
further follow-up. We resolved discrepancies through discussion.
Data extraction and management
Two review authors (KG and FS or LHE) independently extracted
the following data.
• Outcome data (for each outcome and for each treatment
arm whenever applicable):
◦ number of participants randomised;
◦ number of participants included for the analysis;
◦ number of participants with events for binary
outcomes, mean and standard deviation for continuous
outcomes, number of events for count outcomes, and the
number of participants with events and the mean follow-up
period for time-to-event outcomes;
◦ definition of outcomes or scale used if appropriate.
• Data on potential effect modifiers:
◦ participant characteristics such as age, sex,
comorbidities, proportion of symptomatic participants,
proportion with AMA-positive status, proportion of participants
with overlap syndrome, and responders;
◦ details of the intervention and control (including dose,
frequency, and duration);
◦ risk of bias (assessment of risk of bias in included
studies).
• Other data:
◦ year and language of publication;
◦ country in which the participants were recruited;
◦ year(s) in which the trial was conducted;
◦ inclusion and exclusion criteria;
◦ follow-up time points of the outcome.
If available, we planned to obtain the data separately for symp-
tomatic participants and asymptomatic participants from the re-
port. If available, we also planned to obtain the data separately
for people with AMA-positive status and people with AMA-neg-
ative status and for responders and non-responders separately. We
sought unclear or missing information by contacting the trial au-
thors. If there was any doubt whether trials shared the same par-
ticipants, completely or partially (by identifying common authors
and centres), we attempted to contact the trial authors to clarify
whether the trial report was duplicated. We resolved any differ-
ences in opinion through discussion.
Assessment of risk of bias in included studies
We followed the guidance given in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011) and described in
the Cochrane Hepato-Biliary Module (Gluud 2017) to assess the
risk of bias in included trials. Specifically, we assessed the risk of
bias in included trials for the following domains using themethods
below (Schulz 1995; Moher 1998; Kjaergard 2001; Wood 2008;
Savovi 2012a; Savovi 2012b; Lundh 2017).
Allocation sequence generation
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, and throwing
dice were adequate if performed by an independent person not
otherwise involved in the trial.
• Unclear risk of bias: the method of sequence generation was
not specified.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (e.g. if
the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the method used to conceal the
allocation was not described so that intervention allocations may
have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but the review authors judged that the
outcome was not likely to be influenced by lack of blinding; or
blinding of participants and key study personnel ensured, and it
was unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome was likely to be
influenced by lack of blinding; or blinding of key study
participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome was likely to
be influenced by lack of blinding.
Blinding of outcome assessors
• Low risk of bias: any of the following: no blinding of
outcome assessment, but the review authors judged that the
outcome measurement was not likely to be influenced by lack of
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blinding; or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement was likely
to be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement was likely to be influenced by
lack of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. Sufficient
methods, such as multiple imputation, were employed to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported at least the following
predefined outcomes: mortality, decompensated liver disease,
requirement for transplantation, or treatment-related adverse
events. If the original trial protocol was available, the outcomes
should have been those called for in that protocol. If the trial
protocol was obtained from a trial registry (e.g.
www.clinicaltrials.gov), the outcomes sought should have been
those enumerated in the original protocol if the trial protocol
was registered before or at the time that the trial was begun. If
the trial protocol was registered after the trial was begun, those
outcomes were not considered to be reliable.
• Unclear risk: not all predefined, or clinically relevant and
reasonably expected, outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.
• High risk: one or more predefined or clinically relevant and
reasonably expected outcomes were not reported, even though
data on these outcomes were likely to have been available and
even recorded.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that may
manipulate the trial design, conductance, or results of the trial.
• Unclear risk of bias: the trial may or may not have been free
of for-profit bias as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
components (e.g. inappropriate control or dose or
administration of control) that could put it at risk of bias.
• Unclear risk of bias: the trial may or may not have been free
of other components that could put it at risk of bias.
• High risk of bias: there are other factors in the trial that
could put it at risk of bias (e.g. inappropriate control or dose or
administration of control).
We considered a trial at low risk of bias if we assessed the trial to
be at low risk of bias across all domains. Otherwise, we considered
trials to be at unclear risk of bias or at high risk of bias regarding
one or more domains as at high risk of bias.
Measures of treatment effect
For dichotomous variables (e.g. short-term and medium-term
mortality, liver transplantation, proportion of participants with
adverse events, decompensated liver disease, cirrhosis, or hepato-
cellular carcinoma), we calculated the odds ratio (OR) with 95%
confidence intervals (CI). For continuous variables (e.g. quality of
life reported on the same scale), we planned to calculate the mean
difference with 95% CI. We planned to use standardised mean
difference values with 95% CI for quality of life if included trials
used different scales. For count outcomes (e.g. number of adverse
events), we calculated the rate ratio with 95% CI. For time-to-
event data (e.g. mortality at maximal follow-up or requirement
for liver transplantation, time to liver decompensation, and time
to cirrhosis), we planned to use the hazard ratio (HR) with 95%
CIs. We also calculated Trial Sequential Analysis-adjusted CI to
control random errors (Thorlund 2011).
Unit of analysis issues
The unit of analysis was people with primary biliary cholangitis
according to the intervention group to which they were randomly
assigned.
Cluster randomised clinical trials
We found no cluster randomised clinical trials. However, if we
had found them, we would have included them provided that the
effect estimate adjusted for cluster correlation was available.
Cross-over randomised clinical trials
If we found cross-over randomised clinical trials, we included the
outcomes after the period of first intervention only since primary
biliary cholangitis is a chronic disease and the interventions could
potentially have a residual effect.
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Trials with multiple treatment groups
We collected data for all trial intervention groups that met our
inclusion criteria.
Dealing with missing data
We performed an intention-to-treat analysis whenever possible
(Newell 1992). Otherwise, we used the data that were available
to us (e.g. a trial may have reported only per-protocol analysis
results). As such per-protocol analyses may be biased, we planned
to conduct best-worst case scenario analysis (good outcome in
intervention group and bad outcome in control group) and worst-
best case scenario analysis (bad outcome in intervention group and
good outcome in control group) as sensitivity analyses whenever
possible.
For continuous outcomes, we planned to impute the standard de-
viation from P values according to guidance given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011). If
the data were likely to be normally distributed, we planned to use
the median for meta-analysis when the mean was not available. If
it was not possible to calculate the standard deviation from the P
value or the CIs, we planned to impute the standard deviation us-
ing the largest standard deviation in other trials for that outcome.
This form of imputation may decrease the weight of the study for
calculation of mean differences and may bias the effect estimate to
no effect for calculation of standardised mean differences (Higgins
2011).
Assessment of heterogeneity
We assessed clinical andmethodological heterogeneity by carefully
examining the characteristics and design of included trials. We
assessed the presence of clinical heterogeneity by comparing effect
estimates in the presence or absence of symptoms, the presence or
absence of AMA, responders versus non-responders, and the doses
of the pharmacological interventions. Different study designs and
risk of bias may contribute to methodological heterogeneity. We
used the I2 test and Chi2 test for heterogeneity, and overlapping
of CIs to assess heterogeneity.
Assessment of reporting biases
We planned to use visual asymmetry on a funnel plot to explore
reporting bias in the presence of at least 10 trials that could be
included for a direct comparison (Egger 1997;Macaskill 2001). In
the presence of heterogeneity that could be explained by subgroup
analysis, we planned to produce a funnel plot for each subgroup in
the presence of an adequate number of trials (at least 10 trials). We
planned to use the linear regression approach described by Egger
1997 to determine funnel plot asymmetry.
We also considered selective reporting as evidence of reporting
bias.
Data synthesis
We performed the meta-analyses according to the recommenda-
tions of Cochrane (Higgins 2011), using the software package Re-
viewManager 5 (RevMan 2014).We used a random-effects model
(DerSimonian 1986) and a fixed-effect model (DeMets 1987). In
the case of a discrepancy between the two models, we reported
both results; otherwise, we reported only the results from the fixed-
effect model.
Calculation of required information size and Trial Sequential
Analysis
For calculation of the required information size, see Appendix 3.
We performed Trial Sequential Analysis to control the risk of ran-
dom errors when there were at least two trials included for mor-
tality at maximal follow-up, serious adverse events (proportion)
and health-related quality of life, the three outcomes that deter-
mine whether an intervention should be used (Wetterslev 2008;
Thorlund 2011; TSA 2011; Wetterslev 2017). We used an alpha
error as per guidance of Jakobsen 2014, power of 90% (beta error
of 10%), a relative risk reduction of 20%, a control group propor-
tion observed in the trials, and the diversity observed in the meta-
analysis.
Subgroup analysis and investigation of heterogeneity
Weplanned to assess the differences in the effect estimates between
the following subgroups.
• Trials at low risk of bias compared to trials at high risk of
bias.
• Participants with symptomatic compared to participants
with asymptomatic primary biliary cholangitis.
• AMA-positive participants compared to AMA-negative
participants.
• Responders compared to non-responders to bile acids.
• Different doses of pharmacological interventions. For
example, various doses of UDCA used in randomised clinical
trials include 5 mg/kg to 7 mg/kg, 13 mg/kg to 15 mg/kg
(moderate dose), and 23 mg/kg to 25 mg/kg (high dose) (Angulo
1999a; Lindor 1997).
Weplanned touse theChi2 test for subgroupdifferences to identify
subgroup differences.
Sensitivity analysis
If a trial reported only per-protocol analysis results, we planned
to re-analyse the results using the best-worst case scenario and
worst-best case scenario analyses as sensitivity analyses whenever
possible.
11Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Presentation of results and GRADE assessments
We reported mortality, serious adverse events, and health-related
quality of life, the three most important outcomes that determine
the use of an intervention in a ’Summary of findings’ table format,
downgrading the quality of evidence for risk of bias, inconsistency,
indirectness, imprecision, and publication bias using GRADE (
Guyatt 2011).We have presented the ’Summary of findings’ tables
for all comparisons in which two trials were included for one of
mortality at maximal follow-up, serious adverse events, or health-
related quality of life.
R E S U L T S
Description of studies
Results of the search
We identified 5592 references through electronic searches ofCEN-
TRAL (n = 1104), MEDLINE (n = 2383), Embase (n = 604), Sci-
ence Citation Index Expanded (n = 1362), World Health Organi-
zation International Clinical Trials Registry Platform (n = 88), and
ClinicalTrials.gov (n = 51). After the removal of 1249 duplicates
we obtained 4343 references.We then excluded 3973 clearly irrel-
evant references through screening titles and reading abstracts. We
retrieved 370 references for further assessment. No references were
identified through scanning reference lists of the identified ran-
domised trials.We excluded 117 references for the reasons stated in
theCharacteristics of excluded studies table.Nine references are an
ongoing trial without any interim data (ChiCTR-IPR-16008935;
EUCTR2015-002698-39-GB;NCT02308111;NCT02701166;
NCT02823353; NCT02823366; NCT02937012;
NCT02943447; NCT02965911). We were unable to obtain the
full texts for two references (O’Brian 1990; Zaman 2006). In total,
242 references (74 trials) met the inclusion criteria. The reference
flow is summarised in the study flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
The 74 trials thatmet the inclusion criteria for this review included
5902 participants. Some 28 trials did not contribute any informa-
tion for this review leaving 4274 participants included in one or
more outcomes in the review (Bodenheimer 1988; Arora 1990;
Oka 1990; Smart 1990; Poupon 1991a; Senior 1991; Battezzati
1993;Manzillo 1993a;Manzillo 1993b; Bobadilla 1994;Goddard
1994; Lim 1994; McCormick 1994; Steenbergen 1994; Lindor
1997; Kaplan 1999; Leuschner 1999; Nakai 2000; Mazzarella
2002; Ueno 2005; Iwasaki 2008a; Iwasaki 2008b; Askari 2010;
Liberopoulos 2010; Cash 2013; Bowlus 2014; Kowdley 2014a;
Mayo 2015). In themain reviewunstratified by the dose of UDCA
or obeticholic acid, 4060 participants were included in one or
more outcomes in the review. The mean or median age of the par-
ticipants ranged from 46 to 64 years in the trials that reported this
information. The proportion of females ranged from 77.8% to
100% in the trials that reported this information. The proportion
of participants with symptoms varied from 19.9% to 100% in the
trials that reported this information. The proportion of partici-
pants who were AMA positive ranged from 80.8% to 100% in
the trials that reported this information. Ten trials included non-
responders to bile acids only (Van Hoogstraten 1998; Wolfhagen
1998; Kanda 2003; Ueno 2005; Iwasaki 2008b; Mason 2008;
Liberopoulos 2010; Hirschfield 2015; Hosonuma 2015; Nevens
2016). The remaining trials did not state whether they included
responders or non-responders, or both. However, it appeared that
most trials included participants who had not received previous
treatments or regardless of the previous treatments received. The
interventions, controls, number of participants included in each
trial, and the follow-up period reported in the different trials are
listed in Table 1.
Source of funding: nine trials receive no additional funding or were
funded by parties with no vested interest in the results (Heathcote
1976; Hoofnagle 1986; Almasio 2000; Nakai 2000; Iwasaki
2008a; Iwasaki 2008b; Askari 2010; Cash 2013; Hosonuma
2015). Thirty-one trials were partially or fully funded by the phar-
maceutical companies that would benefit based on the results of
the trial (Triger 1980; Matloff 1982; Christensen 1985; Dickson
1985; Bodenheimer 1988; Minuk 1988; Oka 1990; Wiesner
1990; Poupon 1991a; Senior 1991; Lombard 1993; Mitchison
1993; Heathcote 1994; Lindor 1994; McCormick 1994; Combes
1995a; Poupon 1996; Eriksson 1997; Van Hoogstraten 1998;
Wolfhagen 1998; Leuschner 1999; Pares 2000; Papatheodoridis
2002; Combes 2005; Rautiainen 2005; Mason 2008; Bowlus
2014; Kowdley 2014a; Mayo 2015; Ma 2016; Nevens 2016). The
source of funding was not available from the 34 remaining trials.
Excluded studies
The reasons for exclusion are summarised in the Characteristics
of excluded studies table. While the reasons for exclusion for most
references were self-explanatory, the reasons for exclusion of 15 ref-
erences required some explanation (Poupon 1994; Lindor 1995a;
Emond1996; Lindor 1996; Angulo 1999b; Angulo 1999c;Degott
1999; Corpechot 2000; Jorgensen 2002; Kaplan 2004; Combes
2005b; Leung 2010; Leung 2011; Kowdley 2015; Carbone 2016).
These 15 references were long-term follow-up reports of included
trials, but the randomisation was not maintained and the ’no in-
tervention’ group received the intervention. While this is accept-
able if some participants crossed over for specific reasons in an in-
tention-to-treat analysis, it is not acceptable if the cross-over from
one group to another was done in a systematic manner. Therefore,
we excluded these references.
Risk of bias in included studies
The risk of bias is summarised in Figure 2, Figure 3, and Table 2.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Twenty trials were at low risk of bias due to random sequence gen-
eration (Dickson 1985;Hoofnagle 1986;Warnes 1987;Mitchison
1989; Battezzati 1993; Mitchison 1993; Steenbergen 1994; Van
Hoogstraten 1998; Wolfhagen 1998; Angulo 1999a; Hendrickse
1999; Leuschner 1999; Almasio 2000; Papatheodoridis 2002;
Mason 2008; Askari 2010; Hirschfield 2015; Hosonuma 2015;
Ma 2016; Nevens 2016). The remaining trials were at unclear risk
of bias.
Twenty-four trials were at low risk of bias due allocation conceal-
ment (Dickson 1985; Neuberger 1985; Hoofnagle 1986; Warnes
1987; Mitchison 1989; Oka 1990; Battezzati 1993; Mitchison
1993; Heathcote 1994; Gonzalezkoch 1997; Van Hoogstraten
1998;Wolfhagen1998; Angulo 1999a;Hendrickse 1999; Almasio
2000; Papatheodoridis 2002; Iwasaki 2008a; Iwasaki 2008b;
Mason 2008; Askari 2010; Cash 2013; Hosonuma 2015; Ma
2016; Nevens 2016). The remaining trials were at unclear risk of
bias.
Sixteen trials were at low risk of both random sequence genera-
tion bias and allocation concealment bias (Dickson 1985; Warnes
1987; Mitchison 1989; Battezzati 1993; Mitchison 1993; Van
Hoogstraten 1998; Wolfhagen 1998; Angulo 1999a; Hendrickse
1999; Almasio 2000; Papatheodoridis 2002; Mason 2008; Askari
2010; Hosonuma 2015;Ma 2016; Nevens 2016); these trials were
considered to be at low risk of selection bias. The remaining trials
were at unclear risk of selection bias.
Blinding
Thirty trials were at low risk of performance bias (Taal 1983;
Christensen 1985; Dickson 1985; Neuberger 1985; Warnes
1987; Bodenheimer 1988; Minuk 1988; Oka 1990; Wiesner
1990; Poupon 1991a; Battezzati 1993; Lombard 1993;Mitchison
1993; Heathcote 1994; Lindor 1994; McCormick 1994; Turner
1994; Combes 1995a; Poupon 1996; Wolfhagen 1998; Angulo
1999a; Kaplan 1999; Almasio 2000; Pares 2000; Ueno 2005;
Mason 2008; Askari 2010; Hirschfield 2015; Ma 2016; Nevens
2016). Thirteen trials were at high risk of performance bias (
Heathcote 1976; Epstein 1979;Hoofnagle 1986;Mitchison 1989;
Van Hoogstraten 1998; Yokomori 2001; Papatheodoridis 2002;
Rautiainen 2005; Iwasaki 2008a; Iwasaki 2008b; Liberopoulos
2010; Cash 2013; Hosonuma 2015). The remaining trials were at
unclear risk of performance bias.
Twenty-nine trials were at low risk of detection bias (Taal 1983;
Christensen 1985; Dickson 1985; Neuberger 1985;Warnes 1987;
Bodenheimer 1988; Oka 1990; Wiesner 1990; Poupon 1991a;
Battezzati 1993; Lombard 1993; Mitchison 1993; Heathcote
1994; Lindor 1994; McCormick 1994; Turner 1994; Combes
1995a; Poupon 1996; Wolfhagen 1998; Angulo 1999a; Kaplan
1999; Almasio 2000; Pares 2000; Ueno 2005; Mason 2008;
Askari 2010; Hirschfield 2015; Ma 2016; Nevens 2016). Thir-
teen trials were at high risk of detection bias (Heathcote 1976;
Epstein 1979;Hoofnagle 1986;Mitchison 1989;VanHoogstraten
1998; Yokomori 2001; Papatheodoridis 2002; Rautiainen 2005;
Iwasaki 2008a; Iwasaki 2008b; Liberopoulos 2010; Cash 2013;
Hosonuma 2015). The remaining trials were at unclear risk of
detection bias.
Twenty-nine trials were at low risk of performance bias and detec-
tion bias (Taal 1983; Christensen 1985; Dickson 1985;Neuberger
1985; Warnes 1987; Bodenheimer 1988; Oka 1990; Wiesner
1990; Poupon 1991a; Battezzati 1993; Lombard 1993;Mitchison
1993; Heathcote 1994; Lindor 1994; McCormick 1994; Turner
1994; Combes 1995a; Poupon 1996; Wolfhagen 1998; Angulo
1999a; Kaplan 1999; Almasio 2000; Pares 2000; Ueno 2005;
Mason 2008; Askari 2010; Hirschfield 2015; Ma 2016; Nevens
2016). Thirteen trials were at high risk of performance bias
and detection bias (Heathcote 1976; Epstein 1979; Hoofnagle
1986; Mitchison 1989; Van Hoogstraten 1998; Yokomori 2001;
Papatheodoridis 2002; Rautiainen 2005; Iwasaki 2008a; Iwasaki
2008b; Liberopoulos 2010; Cash 2013; Hosonuma 2015). The
remaining trials were at unclear risk of performance and detection
bias.
Incomplete outcome data
Fifteen trials were at low risk of attrition bias (Macklon 1982;
Matloff 1982; Hoofnagle 1986; Mitchison 1989; Ferri 1993;
Lombard 1993; McCormick 1994; Turner 1994; Combes 1995a;
Ikeda 1996; Kanda 2003; Combes 2005; Askari 2010; Hirschfield
2015; Hosonuma 2015). Twenty-two trials were at high risk of
attrition bias due to dropouts which may have been related to
the intervention that the participant received (Heathcote 1976;
Christensen 1985; Dickson 1985; Kaplan 1986; Bodenheimer
1988; Leuschner 1989; Oka 1990; Poupon 1991a; Senior 1991;
Battezzati 1993; Mitchison 1993; Raedsch 1993; Lindor 1994;
Eriksson 1997; Kaplan 1999; Leuschner 1999; Almasio 2000;
Papatheodoridis 2002; Rautiainen 2005; Cash 2013;Mayo 2015;
Nevens 2016). The remaining trials were at unclear risk of attrition
bias.
Selective reporting
We were unable to find any protocols published prior to the full
study reports. Seventeen trials were at low risk of due to selecting
outcome reporting (Macklon 1982; Matloff 1982; Taal 1983;
Hoofnagle 1986; Warnes 1987; Minuk 1988; Leuschner 1989;
Wiesner 1990; Lombard 1993; Mitchison 1993; Lindor 1994;
Poupon 1996; Gonzalezkoch 1997; Angulo 1999a; Pares 2000;
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Hosonuma 2015;Nevens 2016). The remaining trials were at high
risk of bias due to selective reporting (reporting bias).
Other potential sources of bias
For profit bias: nine trials receive no additional funding or were
funded by parties with no vested interest in the results and were
at low risk of for-profit bias (Heathcote 1976; Hoofnagle 1986;
Almasio 2000; Nakai 2000; Iwasaki 2008a; Iwasaki 2008b; Askari
2010; Cash 2013; Hosonuma 2015). Thirty-one trials partially or
fully funded by the pharmaceutical companies that would ben-
efit based on the results of the trial were at high risk of for-
profit bias (Triger 1980;Matloff 1982; Christensen 1985;Dickson
1985; Bodenheimer 1988; Minuk 1988; Oka 1990; Wiesner
1990; Poupon 1991a; Senior 1991; Lombard 1993; Mitchison
1993; Heathcote 1994; Lindor 1994; McCormick 1994; Combes
1995a; Poupon 1996; Eriksson 1997; Van Hoogstraten 1998;
Wolfhagen 1998; Leuschner 1999; Pares 2000; Papatheodoridis
2002; Combes 2005; Rautiainen 2005; Mason 2008; Bowlus
2014; Kowdley 2014a; Mayo 2015; Ma 2016; Nevens 2016). The
remaining trials were at unclear risk of for-profit bias.
Six trials were at high risk of other bias: authors presented the
results of only a subgroup of participants without explaining the
reason for this approach (Dickson 1985; Ikeda 1996); a significant
proportion of participants crossed over from placebo to UDCA
(Papatheodoridis 2002); it was unclear whether the participants
continued to take UDCA in both groups (Askari 2010); partic-
ipants continued to take varying doses of UDCA (Hirschfield
2015); and participants were allowed to continue previous pre-
scriptions for primary biliary cholangitis (it was unclear whether
this was balanced across groups) (Cash 2013). The remaining tri-
als were at low risk of other bias.
Overall risk of bias
All trials were at high risk of bias in one or more domains.
Effects of interventions
See: Summary of findings for the main comparison
Ursodeoxycholic acid (UDCA) versus no intervention for primary
biliary cholangitis; Summary of findings 2 Azathioprine versus
no intervention for primary biliary cholangitis; Summary of
findings 3 Colchicine versus no intervention for primary
biliary cholangitis; Summary of findings 4 Ciclosporin versus
no intervention for primary biliary cholangitis; Summary of
findings 5 D-Penicillamine versus no intervention for primary
biliary cholangitis; Summary of findings 6 Colchicine plus
ursodeoxycholic acid (UDCA) versus UDCA for primary
biliary cholangitis; Summary of findings 7 Methotrexate plus
ursodeoxycholic acid (UDCA) versus UDCA for primary biliary
cholangitis
Mortality at maximal follow-up
Twenty-eight trials including 2823 participants reported mor-
tality at maximal follow-up (Heathcote 1976; Epstein 1979;
Macklon 1982; Matloff 1982; Taal 1983; Christensen 1985;
Neuberger 1985; Hoofnagle 1986; Kaplan 1986; Warnes 1987;
Minuk 1988; Leuschner 1989; Mitchison 1989; Wiesner 1990;
Lombard 1993; Mitchison 1993; Heathcote 1994; Lindor 1994;
Turner 1994; Poupon 1996; Gonzalezkoch 1997; Hendrickse
1999; Almasio 2000; Pares 2000; Papatheodoridis 2002; Combes
2005; Hosonuma 2015; Nevens 2016). The period of follow-up
in these trials varied between 11 and 96 months. The propor-
tion of people with mortality (maximal follow-up) was higher in
the methotrexate group (adjusted proportion: 23.3%) than in the
no intervention group (1/30 (3.3%)) (OR 8.83, 95% CI 1.01 to
76.96; 60 participants; 1 trial). The proportion of people with
mortality (maximal follow-up)was lower in the azathioprine group
(adjusted proportion: 53.5%) than in the no intervention group
(72/107 (67.3%)) (OR 0.56, 95% CI 0.32 to 0.98; 224 partici-
pants; 2 trials; I2 = 0%). There was no evidence of a difference in
any of the remaining comparisons (Analysis 1.1).
Mortality (up to one year)
Eight trials including 655 participants reported mortality (up to
year) (Heathcote 1976; Neuberger 1985; Warnes 1987; Minuk
1988; Leuschner 1989; Gonzalezkoch 1997; Almasio 2000;
Nevens 2016). There was no evidence of a difference in any of the
comparisons (Analysis 1.2).
Mortality (one to five years)
Twenty trials including 2168 participants reported mortality
(one to five years) (Epstein 1979; Macklon 1982; Matloff 1982;
Taal 1983; Christensen 1985; Hoofnagle 1986; Kaplan 1986;
Mitchison 1989;Wiesner 1990; Lombard 1993;Mitchison 1993;
Heathcote 1994; Lindor 1994; Turner 1994; Poupon 1996;
Hendrickse 1999; Pares 2000; Papatheodoridis 2002; Combes
2005; Hosonuma 2015). The proportion of people with mortal-
ity (one to five years) was higher in the methotrexate group (ad-
justed proportion: 23.3%) than in the no intervention group (1/
30 (3.3%)) (OR 8.83, 95% CI 1.01 to 76.96; 60 participants; 1
trial). There was no evidence of a difference in any of the remain-
ing comparisons (Analysis 1.3).
Serious adverse events (proportion)
Eleven trials including 1076 participants reported serious ad-
verse events (proportion) (Matloff 1982;Warnes 1987; Leuschner
1989; Lindor 1994; Poupon 1996; Kurihara 2000; Pares 2000;
Kanda 2003; Mason 2008; Hirschfield 2015; Nevens 2016). The
period of follow-up varied from three to 41 months. The propor-
tion of people with serious adverse events (proportion) was higher
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in the D-penicillamine group (adjusted proportion: 28.8%; based
on a control group proportion of 1%) versus the no intervention
group (0/26 (0.0%)) (OR 28.77, 95% CI 1.57 to 526.67; 52 par-
ticipants; 1 trial). The proportion of people with serious adverse
events (proportion) was higher in the obeticholic acid plus UDCA
group (adjusted proportion: 4.1%) versus the UDCA group (19/
143 (13.3%)) (OR 3.58, 95% CI 1.02 to 12.51; 216 participants;
1 trial). There was no evidence of a difference in any of the re-
maining comparisons (Analysis 1.4).
Serious adverse events (number of events)
One trial including 216 participants reported serious adverse
events (number of events) (Nevens 2016). The period of follow-
up was 12 months. There was no evidence of a difference between
the UDCA plus obeticholic acid versus the UDCA groups (Anal-
ysis 1.5).
Adverse events (proportion)
Nineteen trials including 1652 participants reported adverse
events (proportion) (Macklon 1982; Dickson 1985;Minuk 1988;
Leuschner 1989; Wiesner 1990; Ferri 1993; Lombard 1993;
Mitchison 1993; Raedsch 1993; Lindor 1994; Ikeda 1996;
Gonzalezkoch 1997; Kurihara 2000; Pares 2000; Yokomori 2001;
Kanda 2003; Rautiainen 2005; Gao 2012; Hirschfield 2015). The
proportion of people with adverse events (proportion) was higher
in the ciclosporin group (adjusted proportion: 76.2%) versus the
no intervention group (97/189 (51.3%) (OR 3.04, 95% CI 1.98
to 4.68; 390; 3 trials; I2 = 27%), D-penicillamine group (adjusted
proportion: 50.6%) versus the no intervention group (25/135
(18.5%)) (OR 4.51, 95% CI 2.56 to 7.93; 287 participants; 2 tri-
als; I2 = 0%); malotilate group (adjusted proportion: 19.2%) ver-
sus the no intervention group (1/49 (2.0%)) (OR 11.43, 95% CI
1.40 to 93.04; 101participants; 1 trial); and obeticholic acid group
(adjusted proportion: 96.1%) versus the no intervention group
(32/38 (84.2%)) (OR 4.58, 95% CI 1.31 to 15.95; 165 partici-
pants; 1 trial). The proportion of people with adverse events (pro-
portion) was higher in the glucocorticosteroids plus UDCA (ad-
justed proportion: 15.8%) versus the UDCA group (2/61 (3.3%)
(OR 5.54, 95% CI 1.35 to 22.84; 135 participants; 2 trials; I2 =
0%) andmethotrexate plusUDCA (adjusted proportion: 100.0%)
versus theUDCA group (0/12 (0.0%)) (OR 115.00, 95%CI 4.98
to 2657.48; 25 participants; 1 trial). The proportion of people
with adverse events (proportion) was higher in the taurodeoxy-
cholic acid (TUDCA) group (adjusted proportion: 60.0%) ver-
sus the UDCA group (1/15 (6.7%)) (OR 21.00, 95% CI 2.16
to 204.61; 30 participants; 1 trial). There was no evidence of a
difference in any of the remaining comparisons (Analysis 1.6).
Adverse events (number)
Fourteen trials including 1304 participants reported adverse
events (number) (Matloff 1982; Taal 1983; Dickson 1985;
Hoofnagle 1986; Minuk 1988; Wiesner 1990; Lombard 1993;
Mitchison 1993; Ikeda 1996; Gonzalezkoch 1997; Wolfhagen
1998;Hirschfield2015;Hosonuma 2015;Ma2016). The number
of adverse events was higher in the chlorambucil group (adjusted
rate: 57.9 events per 100 participants) versus the no intervention
group (3/11 (27.3 events per 100 participants)) (rate ratio 3.67,
95% CI 1.04 to 12.87; 24 participants; 1 trial); ciclosporin group
(adjusted rate: 84.4 events per 100 participants) versus the no
intervention group (128/189 (67.7 events per 100 participants))
(rate ratio 2.58, 95% CI 1.26 to 5.31; 390 participants; 3 trials;
I2= 69%); D-penicillamine group (adjusted rate: 48.4 events per
100 participants) versus the no intervention group (37/155 (23.9
events per 100 participants)) (rate ratio 2.99, 95%CI 1.04 to 8.63;
303 participants; 3 trials; I2 = 75%), malotilate group (adjusted
rate: 20.7 events per 100 participants) versus the no intervention
group (2/49 (4.1 events per 100 participants)) (rate ratio 6.13,
95% CI 1.38 to 27.14; 101 participants; 1 trial); and obeticholic
acid group (adjusted rate: 175.0 events per 100 participants) ver-
sus the no intervention group (96/38 (252.6 events per 100 par-
ticipants)) (rate ratio 1.41, 95% CI 1.13 to 1.75; 76 participants;
1 trial); ; ; ; . The number of adverse events was higher in the
methotrexate plus UDCA group (adjusted rate: 30.6 events per
100 participants) versus the UDCA group (0/12 (0.0 events per
100 participants)) (rate ratio 30.64, 95% CI 1.84 to 510.76; 27
participants; 1 trial). There was no evidence of a difference in any
of the remaining comparisons (Analysis 1.7).
Health-related quality of life
None of the trials reported health-related quality of life at any time
point.
Liver transplantation
Eleven trials including 1561 participants reported liver trans-
plantation (Neuberger 1985; Wiesner 1990; Lombard 1993;
Heathcote 1994; Lindor 1994; Turner 1994; Eriksson 1997;
Hendrickse 1999; Papatheodoridis 2002; Combes 2005;
Hosonuma 2015). There was no evidence of a difference in any
of the comparisons (Analysis 1.8).
Decompensated liver disease
Seven trials including 909 participants reported decompen-
sated liver disease (Taal 1983; Combes 1995a; Almasio 2000;
Papatheodoridis 2002; Combes 2005; Gao 2012; Nevens 2016).
There was no evidence of a difference in any of the comparisons
(Analysis 1.9).
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Cirrhosis
Three trials including 103 participants reported cirrhosis (
Heathcote 1976; Turner 1994; Wolfhagen 1998). There was no
evidence of a difference in any of the comparisons (Analysis 1.10).
Hepatocellular carcinoma
None of the trials reported hepatocellular carcinoma.
Subgroup analysis
All the trials were at high risk of bias for one or more domains.
None of the trials reported separate data for symptomatic and
asymptomatic participants, AMA-positive andAMA-negative par-
ticipants, or for responders and non-responders to bile acids. A
secondary analysis performed by stratifying for the doses ofUDCA
and obeticholic acid revealed no differences between the main
analysis except for the following.
There was no evidence of differences in the proportion of people
with adverse events when stratified by the dose of obeticholic acid
(obeticholic acid (high) versus no intervention: OR 16.60, 95%
CI 0.90 to 305.59; 79 participants; 1 trial; obeticholic acid (mod-
erate) versus no intervention: OR 8.81, 95% CI 1.01 to 76.73; 86
participants; 1 trial; and obeticholic acid (low) versus no interven-
tion: OR 1.59, 95% CI 0.41 to 6.17; 76 participants; 1 trial). In
addition, when stratified by dose, only obeticholic acid (high) had
higher number of adverse events than no intervention (rate ratio
1.91, 95% CI 1.50 to 2.44; 79 participants; 1 trial). It also had
higher number of adverse events than obeticholic acid (moder-
ate) and obeticholic acid (low) (obeticholic acid (moderate) versus
obeticholic acid (high): rate ratio 0.66, 95% CI 0.53 to 0.81; 89
participants; 1 trial; obeticholic acid (low) versus obeticholic acid
(high): rate ratio 0.55, 95% CI 0.43 to 0.70; 79 participants; 1
trial).
Sensitivity analysis
We did not perform a sensitivity analysis of imputing information
based on different scenarios because of paucity of data to carry out
these analyses. We did not impute standard deviation; therefore,
we did not perform a sensitivity analysis to assess the impact of
imputing the standard deviation.
Reporting bias
We did not assess reporting bias by creating a funnel plot because
of the few trials included under each comparison.
Using fixed-effect model versus random-effects model
The interpretation of results was not altered based on the model
used for analysis.
Quality of evidence
The overall quality of evidence was very low for all the out-
comes (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; Summary of findings 6; Summary of
findings 7). This was because of the high risk of bias in all the trials
(downgraded by two levels); small sample sizes for all outcomes
and wide CIs (downgraded by two levels for imprecision) and het-
erogeneity (downgraded by two levels) for some of the outcomes.
Sample size calculations and Trial Sequential Analysis
The required sample size for identifying a 20% relative risk re-
duction in the different outcomes based on an alpha error of 5%,
a beta error of 20%, and the control group proportion observed
across trials were as follows.
• Mortality (up to one year) (control group proportion:
25.2%): 2166 participants.
• Mortality (one to five years) (control group proportion:
20.0%): 2894 participants.
• Mortality at maximal follow-up (control group proportion:
20.8%): 2758 participants.
• Serious adverse events (proportion) (control group
proportion: 0.4%): 175,996 participants.
• Adverse events (proportion) (control group proportion:
27%): 1978 participants.
• Liver transplantation (control group proportion: 7.4%):
8910 participants.
• Decompensated liver disease (control group proportion:
20.8%): 2758 participants.
• Cirrhosis (control group proportion: 55.6%): 632
participants.
The above mentioned are sample sizes uncorrected for heterogene-
ity. In the presence of heterogeneity, for example, in the presence
of a heterogeneity of 27%, the required information size for ad-
verse events (proportion) is 1978/(1 - 0.27) = 2710 participants.
As shown in Figure 4, Figure 5, and Figure 6, the accrued sample
sizes were only small fractions of the diversity-adjusted required
information size (DARIS) and therefore, the boundaries could not
be drawn. There was a high risk of random errors. The TSA-ad-
justed CI could not be calculated as there was too little informa-
tion for the calculation (i.e. the CIs were wide).
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Figure 4. Trial Sequential Analysis of mortality at maximal follow-up: azathioprine versus no intervention
and colchicine versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a
relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 20%), and diversity
observed in the analyses (0%), the accrued sample size (224 for azathioprine versus intervention and 122 for
colchicine versus no intervention) was only a small fraction of the diversity adjusted required information size
(DARIS) (4580 for both comparisons); therefore, the trial sequential monitoring boundaries were not drawn.
The Z-curve (blue line) crossed the conventional boundaries (dotted green line) favouring azathioprine for
azathioprine versus no intervention, but did not cross the conventional boundaries for colchicine versus no
intervention. This indicates that there is a high risk of random errors in both these comparisons.
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Figure 5. Trial Sequential Analysis of mortality at maximal follow-up: ciclosporin versus no intervention and
D-penicillamine versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a
relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 20%), and diversity
observed in the analyses (82% for ciclosporin versus no intervention and 61% for D-penicillamine versus no
intervention), the accrued sample size (394 for ciclosporin versus no intervention and 423 for D-penicillamine
versus no intervention) was only a small fraction of the diversity adjusted required information size (DARIS)
(25,098 for ciclosporin versus no intervention and 11,623 for D-penicillamine versus no intervention);
therefore, the trial sequential monitoring boundaries were not drawn. The Z-curve (blue line) crossed the
conventional boundaries (dotted green line) favouring ciclosporin for ciclosporin versus no intervention, but
did not cross the conventional boundaries for D-penicillamine versus no intervention. This indicates that there
is a high risk of random errors in both these comparisons.
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Figure 6. Trial Sequential Analysis of mortality at maximal follow-up: colchicine plus UDCA versus
UDCA.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of
20%, a control group proportion observed in the trials (Pc = 7.8%), and diversity observed in the analyses (0%),
the accrued sample size (160 participants) was only a small fraction of the diversity adjusted required
information size (DARIS) (13,316); therefore, the trial sequential monitoring boundaries were not drawn. The
Z-curve (blue line) did not cross the conventional boundaries (green dotted line). This indicates that there is a
high risk of random errors in both this comparison.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Azathioprine versus no intervention for primary biliary cholangitis
Patient or population: people with primary biliary cholangit is
Settings: secondary or tert iary care
Intervention: azathioprine
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Azathioprine
M ortality at maximal fol-
low-up
Follow-up: 63 months in 1
trial and not stated in 1 trial
208 per 1000 128 per 1000
(78 to 205)
OR 0.56
(0.32 to 0.98)
224
(2 trials)
⊕©©©
Very low1,2
Serious adverse events
(proportion)
None of the trials reported this outcome.
Serious adverse events
(number of events)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group proport ion across all the trials. The corresponding risk (and its 95% conf idence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias in the trial(s) was high (downgraded by two levels).
2 Sample sizes were small and 95% conf idence intervals overlapped clinically signif icant and clinically insignif icant or no
ef fect (downgraded by two levels).
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Colchicine versus no intervention for primary biliary cholangitis
Patient or population: people with primary biliary cholangit is
Settings: secondary or tert iary care
Intervention: colchicine
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Colchicine
M ortality at maximal fol-
low-up
Follow-up: 12 to 24 months
208 per 1000 168 per 1000
(78 to 327)
OR 0.77
(0.32 to 1.85)
122
(2 trials)
⊕©©©
Very low1,2
Serious adverse events
(proportion)
Follow-up: 12 months
There were no events in either group 64
(1 trial)
⊕©©©
Very low1,2,3
Serious adverse events
(number of events)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group proport ion across all the trials. The corresponding risk (and its 95% conf idence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.26
P
h
a
rm
a
c
o
lo
g
ic
a
l
in
te
r
v
e
n
tio
n
s
fo
r
p
rim
a
ry
b
ilia
ry
c
h
o
la
n
g
itis:
a
n
a
tte
m
p
te
d
n
e
tw
o
rk
m
e
ta
-a
n
a
ly
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
1 Risk of bias in the trial(s) was high (downgraded by two levels).
2 Sample sizes were small and 95% conf idence intervals overlapped clinically signif icant and clinically insignif icant or no
ef fect (downgraded by two levels).
3 There was moderate heterogeneity (downgraded by one level).
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Ciclosporin versus no intervention for primary biliary cholangitis
Patient or population: people with primary biliary cholangit is
Settings: secondary or tert iary care
Intervention: ciclosporin
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Ciclosporin
M ortality at maximal fol-
low-up
Follow-up: 31 to 35 months
208 per 1000 188 per 1000
(118 to 283)
OR 0.88
(0.51 to 1.50)
390
(3 trials)
⊕©©©
Very low1,2
Serious adverse events
(proportion)
None of the trials reported this outcome.
Serious adverse events
(number of events)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group proport ion across all the trials. The corresponding risk (and its 95% conf idence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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1 Risk of bias in the trial(s) was high (downgraded by two levels).
2 Sample sizes were small and 95% conf idence intervals overlapped clinically signif icant and clinically insignif icant or no
ef fect (downgraded by two levels).
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D-Penicillamine versus no intervention for primary biliary cholangitis
Patient or population: people with primary biliary cholangit is
Settings: secondary or tert iary care
Intervention: D-penicillam ine
Comparison: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention D-Penicillamine
M ortality at maximal fol-
low-up
(Follow-up 24 to 66 months)
208 per 1000 191 per 1000
(130 to 274)
OR 0.90
(0.57 to 1.44)
423
(5 trials)
⊕©©©
Very low1,2,3
Serious adverse events
(proportion)
(Follow-up 24 months)
4 per 1000 104 per 1000
(6 to 679)
OR 28.77
(1.57 to 526.67)
52
(1 trial)
⊕©©©
Very low1,2,3
Serious adverse events
(number of events)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group proport ion across all the trials. The corresponding risk (and its 95% conf idence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.30
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1 Risk of bias in the trial(s) was high (downgraded by two levels).
2 Sample sizes were small and 95% conf idence intervals overlapped clinically signif icant and clinically insignif icant or no
ef fect (downgraded by two levels).
3 There was moderate heterogeneity (downgraded by one level).
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Colchicine plus UDCA versus UDCA for primary biliary cholangitis
Patient or population: people with primary biliary cholangit is
Settings: secondary or tert iary care
Intervention: colchicine + UDCA
Comparison: UDCA
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
UDCA Colchicine + UDCA
M ortality at maximal fol-
low-up
Follow-up: 24 months in 1
trial; not reported in 1 trial
110 per 1000 185 per 1000
(45 to 524)
OR 1.84
(0.38 to 8.91)
158
(2 trials)
⊕©©©
Very low1,2
Serious adverse events
(proportion)
Follow-up: not stated
14 per 1000 42 per 1000
(2 to 526)
OR 3.08
(0.12 to 78.14)
74
(1 trial)
⊕©©©
Very low1,2,3
Serious adverse events
(number of events)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group proport ion across all the trials. The corresponding risk (and its 95% conf idence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io; UDCA: ursodeoxycholic acid.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias in the trial(s) was high (downgraded by two levels).
2 Sample sizes were small and 95% conf idence intervals overlapped clinically signif icant and clinically insignif icant or no
ef fect (downgraded by two levels).
3 There was moderate heterogeneity (downgraded by one level).
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M ethotrexate plus UDCA versus UDCA for primary biliary cholangitis
Patient or population: people with primary biliary cholangit is
Settings: secondary or tert iary care
Intervention: methotrexate + UDCA
Comparison: UDCA
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
UDCA M ethotrexate + UDCA
M ortality at maximal fol-
low-up
Follow-up: 11 to 91 months
110 per 1000 126 per 1000
(64 to 237)
OR 1.17
(0.55 to 2.51)
290
(2 trials)
⊕©©©
Very low1,2
Serious adverse events
(proportion)
None of the trials reported this outcome.
Serious adverse events
(number of events)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group proport ion across all the trials. The corresponding risk (and its 95% conf idence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io; UDCA: ursodeoxycholic acid.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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1 Risk of bias in the trial(s) was high (downgraded by two levels).
2 Sample sizes were small and 95% conf idence intervals overlapped clinically signif icant and clinically insignif icant or no
ef fect (downgraded by two levels).
3 There was moderate heterogeneity (downgraded by one level).
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D I S C U S S I O N
Summary of main results
We included 74 trials (5902 participants) in this review, and in-
cluded 4274 participants from 46 trials in one or more outcomes
in this review. We did not perform the planned network meta-
analysis because there was no closed loop (i.e. outcomes for which
direct and indirect estimates were available to allow us estimation
of inconsistency). Therefore, we reported only the direct compar-
isons. We reported the results from frequentist meta-analysis only
as it is more familiar to people.
Althoughmortality at maximal follow-up was lower in people who
received azathioprine versus no intervention, therewas no evidence
of any reduction in mortality by any intervention, either at less
thanone year or betweenone andfive years.However, this evidence
is unreliable because the Christensen 1985 trial excluded a large
proportion of participants (25%) (i.e. only 185/224 participants
were included in the meta-analysis). The Trial Sequential Analysis
showed that only a small proportion of the required information
sizewas reached and the risk of randomerrorswas high. In addition
to the risk of systematic errors and random errors, the proportion
of people who died was high (71.3%) in the no intervention group
of the Christensen 1985 trial compared to the other trials (the
overall mortality at maximal follow-up was 20.8%). Although this
difference could be due to the shorter follow-up periods in some of
the other trials, themortality observed in this trial wasmuch higher
than that observed in the other trials with similar or longer follow-
up such as Epstein 1979; Hendrickse 1999; and Papatheodoridis
2002. The general care of people with cirrhosis is likely to have
improved since the 1980s and it is unlikely to be as high as that
mortality observed in Christensen 1985. This is another reason
why there is no need to recommend azathioprine routinely in
people with primary biliary cholangitis.
There was no evidence of a decrease in liver transplantation, de-
compensated liver disease, or cirrhosis in any of the interventions
compared with no intervention. However, several interventions
increased the number of people with, and total number of, adverse
events. Although the Trial Sequential Analysis revealed that only
a small proportion of the required information size was reached,
the risk of random errors was high. Thus, concluding that there
were more adverse events in some of these comparisons is only of
academic interest because none of the interventions appeared to
result in clinical benefit.
However, it has to be pointed out that the periods of follow-up
in the trials were sufficiently long to identify any differences in
clinical outcomes because primary biliary cholangitis is a slowly
progressive disease. Trials with sufficient follow-up (e.g. five or 10
years) are required to detect any differences in clinically important
outcomes.
Overall completeness and applicability of
evidence
The trials included symptomatic and asymptomatic primary bil-
iary cholangitis, AMA-positive and AMA-negative primary bil-
iary cholangitis, treatment-naive people, and people regardless of
the treatments that they had received previously. However, ma-
jority of the trials excluded people with advanced liver cirrhosis
and primary biliary cholangitis in people with other liver diseases.
Therefore, this review is applicable to people with primary bil-
iary cholangitis without advanced liver cirrhosis or with coexisting
other liver diseases.
Quality of the evidence
The overall quality of evidence was very low for all the outcomes.
The major reasons for this were the high risk of bias in the tri-
als, in particular, exclusion of participants from the analysis after
randomisation, small sample size, and imprecision. Overall, there
were serious concerns about whether the effect estimates observed
were the true effect estimates.
Potential biases in the review process
We followed the guidance of theCochrane Handbook for Systematic
Reviews of Interventions with two review authors independently
selecting trials and extracting data (Higgins 2011). We performed
a thorough search of the literature. However, the search period in-
cludes the premandatory trial registration era and it is possible that
some trials on treatments that were not effective or were harmful
were not reported at all.
We excluded studies which compared variations in the different
treatments. Hence, this review does not provide information on
whether one variation is better than another.
We only included randomised clinical trials which are known to
focus mostly on benefits and do not collect and report harms in
a detailed manner. Therefore, we might have missed a large num-
ber of studies that addressed the reporting of harms. Accordingly,
this review is biased towards benefits ignoring harms. We did not
search for interventions and trials registered at regulatory authori-
ties (e.g. US Food and Drug Administration; EuropeanMedicines
Agency, etc.). This may have overlooked trials and as such trials
usually are unpublished, the lack of inclusion of such trials may
make our comparisons look more advantageous than they really
are. However, this is of academic interest only because there is no
evidence of benefit of any treatment in people with primary bil-
iary cholangitis (i.e. there is no reason to suggest that any of the
treatments should be used in routine clinical practice regardless of
the adverse event profile of the intervention).
We planned to perform a network meta-analysis. However, it was
not possible to assess whether the potential effect modifiers were
similar across different comparisons. Performing a network meta-
analysis in this scenario can be misleading. Therefore, we did not
perform the network meta-analysis, and assessed the compara-
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tive benefits and harms of different interventions using standard
Cochrane methodology.
Agreements and disagreements with other
studies or reviews
We identified three network meta-analyses on this topic (Zhu
2015a; Zhu 2015b; Zhu 2015c). We disagreed with the authors
of these reviews that UDCA in combination with corticosteroids
or methotrexate are effective interventions in the treatment of pri-
mary biliary cholangitis. The disagreements were probably due to
considering mortality and liver transplantation separately in this
review compared to Zhu 2015a and Zhu 2015b and only includ-
ing evidence prior to cross-over in our review. In particular, the
cross-over was not true cross-over where the interventions were
swapped but all the participants belonging to the ’no intervention’
were switched over to the intervention. Therefore, it was not possi-
ble to obtain the effect estimate adjusted for intra-participant cor-
relation either. It should be also noted that the decision to switch
the no intervention to intervention was based on improvement of
some laboratory parameters which are invalidated surrogate out-
comes. This can only be considered as observational evidence. We
disagree with current EASL and AASLD guideline recommenda-
tions that UDCA should be used for the management of primary
biliary cholangitis (EASL 2009; Lindor 2009). Again, these rec-
ommendations were based on observational evidence and invali-
dated surrogate outcomes (Gluud 2007).
We agreedwith several systematic reviews that showed that none of
the interventions are effective in improving survival or othermajor
clinical outcomes such as cirrhosis or liver transplantation (Giljaca
2010; Rudic 2012a; Rudic 2012b; Yin 2015; Zhang 2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on very low quality evidence, there is currently no evidence
that any intervention is beneficial for primary biliary cholangitis.
Implications for research
Randomised clinical trials need to be conducted and reported ac-
cording to the SPIRIT (Standard Protocol Items: Recommenda-
tions for Interventional Trials) statement (Chan 2013) and the
CONSORT statement (Schulz 2010). Future randomised clinical
trials ought to be adequately powered, performed in people who
are generally seen in the clinic rather than in highly selected par-
ticipants, employ blinding, avoid post-randomisation dropouts or
planned cross-overs, should have sufficient follow-up period (e.g.
five to 10 years or more), and use clinically important outcomes
such as mortality, health-related quality of life, cirrhosis, decom-
pensated cirrhosis, and liver transplantation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Almasio 2000
Methods Randomised clinical trial.
Participants Country: Italy.
Number randomised: 90.
Post-randomisation dropouts: 6 (6.7%).
Revised sample size: 84.
Mean age: 54 years.
Females: 81 (96.4%).
Symptomatic participants: 84 (100%).
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: symptomatic participants only.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• People with biliary obstruction.
• Anticipated requirement for liver transplantation in 1 year.
• Pregnancy.
• Aged < 18 years or > 70 years.
• Coexisting liver disease.
• Anticipated life expectancy < 3 years.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) + colchicine (n = 42).
Further details: UDCA: 250 mg BD for 3 years + colchicine: 1 mg/day for 3 years
Group 2: UDCA (low) (n = 42).
Further details: UDCA: 250 mg BD for 3 years.
Outcomes Mortality, decompensated liver disease.
Notes Reasons for post-randomisation dropouts: adverse effects and low compliance
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Colchicine, 1 mg daily, or an indistinguishable
placebo were randomly assigned to patients according to a
computer-generated list developed separately for each cen-
tre”
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed by a central study
unit…”
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Almasio 2000 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used and authors stated dou-
ble-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used and authors stated dou-
ble-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
For-profit bias Low risk Comment: no money received for the trial; the drug was
provided by Abc Farmaceutici S.p.a (author’s reply)
Other bias Low risk Comment: no other bias noted.
Angulo 1999a
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 155.
Post-randomisation dropouts: not stated.
Revised sample size: 155.
Mean age: 53 years.
Females: 130 (83.9%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 12 months
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• People with decompensated cirrhosis.
• Hepatocellular carcinoma.
• Concomitant immunosuppressive regimen.
• Other major diseases unrelated to primary biliary cholangitis.
• Alcohol abuse.
• Low compliance.
Interventions Participants were randomly assigned to 3 groups.
Group 1: UDCA (low) (n = 52).
Further details: UDCA: 5 mg/kg/day to 7 mg/kg/day; duration: 1 to 2 years
Group 2: UDCA (moderate) (n = 49).
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Angulo 1999a (Continued)
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day; duration: 1 to 2 years
Group 3: UDCA (high) (n = 54).
Further details: UDCA: 23 mg/kg/day to 25 mg/kg/day; duration: 1 to 2 years
Outcomes Mortality, adverse events, liver transplantation.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was carried out separately for each
of the eight strata with a computer-generated, blocked, ran-
domized drug assignment schedule”
Allocation concealment (selection bias) Low risk Quote: “Patients were randomized by a statistician (D.W.
M.), and the drug was provided by a pharmacist who was
not involved in the patient’s clinical evaluation or follow-
up”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patients, physicians, nurses, and study coordi-
nator were unaware throughout the study which dose was
being administered. To assure blindness patients received
the same number of tablets by mixing UDCA-tablets with
placebo-tablets in a ratio defined by their assigned dose;
therefore, the number of tablets taken per day according to
the body weight was exactly the same regardless of the dose
assigned”.
Comment: identical placebo used and authors stated dou-
ble-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used and authors stated dou-
ble-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: unclear whether all participants randomised
were included in the analysis
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other risk of bias.
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Arora 1990
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 9.
Post-randomisation dropouts: not stated.
Revised sample size: 9.
Mean age: not stated.
Females: not stated.
Symptomatic participants: 9 (100%).
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 5 months
Inclusion criteria
• Symptom status: symptomatic participants only.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) (n = 5).
Further details: UDCA: 10 mg/kg/day for 5 months.
Group 2: placebo (n = 4).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: placebo used and authors stated double blind;
however, unclear whether identical placebo used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: placebo used and authors stated double blind;
however, unclear whether identical placebo used
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
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Other bias Low risk Comment: no other risk of bias.
Askari 2010
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 28.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 28.
Mean age: 54 years.
Females: 26 (92.9%).
Symptomatic participants: not stated.
AMA positive: 27 (96.4%).
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• Did not take UDCA in the previous 3 months.
• Decompensated cirrhosis.
• Required renal dialysis.
• Pregnant or nursing.
• Had a serious illness of other types such as uncontrolled congestive heart failure,
severe diabetic neuropathy, severe pulmonary disease, advanced cancer, etc.
Interventions Participants were randomly assigned to 2 groups.
Group 1: tetrathiomolybdate (n = 13).
Further details: tetrathiomolybdate: 10 mg/day to 120 mg/day based on serum cerulo-
plasmin levels; duration: not stated
Group 2: placebo (n = 15).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The patients were assigned to the placebo arm or
the tetrathiomolybdate arm using a table of random num-
bers”
Allocation concealment (selection bias) Low risk Quote: “Central allocation by pharmacy” (author’s reply).
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used and authors stated dou-
ble-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used and authors stated dou-
ble-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “There were not post-randomisation drop-outs”
(author’s reply)
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Low risk Quote: “Supported by Grant FD-02590-02 from the U.
S. Food and Drug Administration’s Orphan Products Of-
fice, the General Clinical Research Center of the University
of Michigan Hospitals, Grant MO1- RR000042 from the
National Institutes of Health, and Grant Ul1- RR024986
Clinical and Translational Science Awards”
Other bias High risk Comment: unclear whether the participants continued to
take UDCA in both groups
Battezzati 1993
Methods Randomised clinical trial.
Participants Country: Italy.
Number randomised: 88.
Post-randomisation dropouts: 2 (2.3%).
Revised sample size: 86.
Mean age: 55 years.
Females: 78 (90.7%).
Symptomatic participants: 86 (100%).
AMA positive: 77 (89.5%).
Responders: not stated.
Mean follow-up period (for all groups): minimum 6 months.
Inclusion criteria
• Symptom status: symptomatic participants only.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• Serum bilirubin levels > 10 mg/dL.
• Decompensated liver disease.
• Evidence of malignancy.
• Alcohol abuse.
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Battezzati 1993 (Continued)
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) (n = 42).
Further details: UDCA: 250 mg BD for 6 months.
Group 2: placebo (n = 44).
Outcomes None of the outcomes of interest reported.
Notes Reasons for post-randomisation dropouts: lost to follow-up.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization of treatment assignments was per-
formed separately for each centre: patients were consecu-
tively given indistinguishable medications, which had been
assigned by the central pharmacy according to a computer-
generated list. UDCA and an identical-appearing placebo
were obtained through the courtesy of ABC Farmaceutici,
Torino, Italy”
Allocation concealment (selection bias) Low risk Quote: “Randomization of treatment assignments was per-
formed separately for each centre: patients were consecu-
tively given indistinguishable medications, which had been
assigned by the central pharmacy according to a computer-
generated list. UDCA and an identical-appearing placebo
were obtained through the courtesy of ABC Farmaceutici,
Torino, Italy”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Randomization of treatment assignments was per-
formed separately for each centre: patients were consecu-
tively given indistinguishable medications, which had been
assigned by the central pharmacy according to a computer-
generated list. UDCA and an identical-appearing placebo
were obtained through the courtesy of ABC Farmaceutici,
Torino, Italy”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Randomization of treatment assignments was per-
formed separately for each centre: patients were consecu-
tively given indistinguishable medications, which had been
assigned by the central pharmacy according to a computer-
generated list. UDCA and an identical-appearing placebo
were obtained through the courtesy of ABC Farmaceutici,
Torino, Italy”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
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Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other risk of bias.
Bobadilla 1994
Methods Randomised clinical trial.
Participants Country: Mexico.
Number randomised: 40.
Post-randomisation dropouts: not stated.
Revised sample size: 40.
Mean age: not stated.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 12 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) + colchicine (n = 21).
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day for 1 year + colchicine: 1 mg/
day for 5 days in a week for 1 year
Group 2: placebo (n = 19).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although placebo used in double-blind trial, un-
clear whether the placebo was identical
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although placebo used in double-blind trial, un-
clear whether the placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
Bodenheimer 1988
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 57.
Post-randomisation dropouts: 10 (17.5%).
Revised sample size: 47.
Mean age: 52 years.
Females: not stated.
Symptomatic participants: 45 (95.7%).
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): 33 months.
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: colchicine (n = 28).
Further details: colchicine: 0.6 mg BD orally for 5 years.
Group 2: placebo (n = 29).
Outcomes None of the outcomes of interest reported.
Notes Reasons for post-randomisation dropouts: non-compliance.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
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Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The design of our trial was that of a double-blind,
randomized evaluation of colchicine (0.6 mg) twice daily
compared with an identically appearing placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The design of our trial was that of a double-blind,
randomized evaluation of colchicine (0.6 mg) twice daily
compared with an identically appearing placebo”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias High risk Quote: “The colchicine and placebo tablets were prepared
and generously supplied by Eli Lilly and Company, Indi-
anapolis, Ind”
Other bias Low risk Comment: no other source of bias.
Bowlus 2014
Methods Randomised clinical trial.
Participants Country: multicentric; international.
Number randomised: 216.
Post-randomisation dropouts: not stated.
Revised sample size: 216.
Mean age: 56 years.
Females: 197 (91.2%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 12 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 3 groups.
Group 1: obeticholic acid (low) (n = 73).
Further details: obeticholic acid (low): 5 mg orally for 12 months; frequency not stated
Group 2: obeticholic acid (low) (n = 73).
Further details: obeticholic acid (low): 10 mg orally for 12 months; frequency not stated
Group 3: placebo (n = 70).
Outcomes None of the outcomes of interest reported.
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Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although placebowas used in double-blind trial,
unclear whether the placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although placebowas used in double-blind trial,
unclear whether the placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias High risk Comment: Several authors had advised pharmaceutical
companies or were employees of pharmaceutical company
Other bias Low risk Comment: no other source of bias.
Cash 2013
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 21.
Post-randomisation dropouts: 8 (38.1%).
Revised sample size: 13.
Mean age: 55 years.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: 13 (100%).
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 12 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: AMA-positive participants only.
• Response status: not stated.
Exclusion criteria
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• Aged < 19 years or > 76 years.
• Cholesterol < 5 mmol/L.
• Known hypertension.
• Diabetes mellitus.
• History of cardiovascular disease.
• Already prescribed lipid-lowering agents or hormonal preparations.
• Pregnancy.
Interventions Participants were randomly assigned to 2 groups.
Group 1: simvastatin (n = 7).
Further details: simvastatin: 20 mg/day orally for 12 months
Group 2: placebo (n = 6).
Outcomes None of the outcomes of interest reported.
Notes Reasons for post-randomisation dropouts: adverse effects.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Low risk Quote: “Patient treatment randomization and allocation
was performed independently by the Department of Re-
search Pharmacology in the Royal Victoria Hospital at the
initial baseline visit”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The patients were blinded but the healthcare
providers were not” (author’s reply)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Outcome assessors were not blinded” (author’s re-
ply)
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Low risk Quote: “Financial support: The Royal Victoria Hospital
Liver Support Group”
Other bias High risk Quote: “Patients were allowed to continue previous pre-
scriptions for primary biliary cholangitis. It was not clear
whether this was balanced across groups”
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Christensen 1985
Methods Randomised clinical trial.
Participants Country: multicentric; international.
Number randomised: 248.
Post-randomisation dropouts: 63 (25.4%).
Revised sample size: 185.
Mean age: 55 years.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: not stated.
Mean follow-up period (for all groups): minimum 63 months.
Inclusion criteria
• Symptom status: not stated.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• No antimetabolites in the previous 6 months.
Interventions Participants were randomly assigned to 2 groups.
Group 1: azathioprine (n = 98).
Further details: azathioprine: escalating doses up to amaximumof 100mg/day; duration:
not stated
Group 2: placebo (n = 87).
Outcomes Mortality.
Notes Reasons for post-randomisation dropouts: lost to follow-up.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomized to azathioprine or
placebo separately for each centre and for each sex by the
sealed envelope technique”
Comment: further details of sealed envelope techniquewere
not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used and authors stated dou-
ble-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used and authors stated dou-
ble-blind
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Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
For-profit bias High risk Quote: “This work was also supported by the Wellcome
Foundation. J.N. was supported by Ciba-Geigy Ltd”
Other bias Low risk Comment: no other source of bias.
Combes 1995a
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 151.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 151.
Mean age: 49 years.
Females: 134 (88.7%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 24 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Other exclusion criteria
• Recurrent bleeds from oesophagogastric varices, spontaneous encephalopathy, or
diuretic-resistant ascites.
• Serum bilirubin ≥ 20 mg/dL.
• Pregnancy.
• Aged < 19 years.
• Findings of other causes of liver disease.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) (n = 77).
Further details: UDCA: 10 mg/kg/day to 12 mg/kg/day for 2 years
Group 2: placebo (n = 74).
Outcomes Decompensated liver disease.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias High risk Quote: “Supported in part by a research grant from Ciba-
Geigy”
Other bias Low risk Comment: no other risk of bias.
Combes 2005
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 265.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 265.
Mean age: 51 years.
Females: 245 (92.5%).
Symptomatic participants: not stated.
AMA positive: 265 (100%).
Responders: not stated.
Median follow-up period (for all groups): 91 months.
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: AMA-positive participants only.
• Response status: not stated.
Exclusion criteria
• People with advanced biliary cirrhosis.
• People with decompensated cirrhosis.
• Aged < 19 years or > 69 years.
• History of alcohol abuse.
• Pregnant or unwilling to use contraception.
• Use of immunosuppressive agents.
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• Renal or pulmonary dysfunction.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) + methotrexate (n = 132).
Further details: UDCA: 15 mg/kg/day for 2 years + methotrexate: 2.5 mg orally once a
week
Group 2: UDCA (moderate) (n = 133).
Further details: UDCA: 15 mg/kg/day for 2 years.
Outcomes Mortality, liver transplantation, decompensated liver disease
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: placebo used in this double-blind trial; however,
the authors did not state whether the placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: placebo used in this double-blind trial; however,
the authors did not state whether the placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
For-profit bias High risk Quote: “By provision of UDCA by Ciba-Geigy Corpora-
tion, and subsequentlyNovartis; by provision ofmethotrex-
ate and its placebo by Lederle Laboratories, and subse-
quently Wyeth-Ayerst Laboratories”
Other bias Low risk Comment: no other source of bias.
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Dickson 1985
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 309.
Post-randomisation dropouts: 82 (26.5%).
Revised sample size: 227.
Mean age: not stated.
Females: 200 (88.1%).
Symptomatic participants: 182 (80.2%).
AMA positive: not stated.
Responders: not stated.
Median follow-up period (for all groups): 60 months.
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• People with severe hepatitis.
• Evidence of inflammatory bowel disease.
• Malignant condition other than skin cancer.
• Evidence of prior or present extrahepatic obstruction.
• Use of cholestatic or hepatotoxic drugs.
• Excessive alcohol intake.
• Presence of hepatitis B antigen.
Interventions Participants were randomly assigned to 2 groups.
Group 1: D-penicillamine (n = 111).
Further details: D-penicillamine: 1000 mg/day; duration: not stated
Group 2: placebo (n = 116).
Outcomes Adverse events.
Notes Reasons for post-randomisation dropouts: histological stages < 3; alcoholism
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned to drug or placebo
groups according to a table of random numbers”
Allocation concealment (selection bias) Low risk Quote: “Penicillamine andplacebo (furnished tous through
the courtesy of Merck Sharp and Dohme, West Point, Pa.
) were dispensed in identical yellow capsules by a central
pharmacist”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in double-blind trial.
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias High risk Quote: “Penicillamine andplacebo (furnished tous through
the courtesy of Merck Sharp and Dohme, West Point, Pa.
) were dispensed in identical yellow capsules by a central
pharmacist”
Other bias High risk Comment: authors presented the results of only a subgroup
of participants without explaining the reason for this
Epstein 1979
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 98.
Post-randomisation dropouts: not stated.
Revised sample size: 98.
Mean age: not stated.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): mean: 66 months.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: D-penicillamine (n = 61).
Further details: D-penicillamine: 600 mg/day to 900 mg/day for 12 months
Group 2: placebo (n = 37).
Outcomes Mortality.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The original double-blind design of the trial was
discontinued after a year because both major and minor
side effects identified treated patients”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The original double-blind design of the trial was
discontinued after a year because both major and minor
side effects identified treated patients”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
Eriksson 1997
Methods Randomised clinical trial.
Participants Country: Sweden.
Number randomised: 116.
Post-randomisation dropouts: 15 (12.9%).
Revised sample size: 101.
Mean age: 57 years.
Females: 99 (98%).
Symptomatic participants: 39 (38.6%).
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 24 months
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• People with severe end-stage liver disease.
• Pregnancy.
• Alcohol or drug abuse.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) (n = 60).
Further details: UDCA: 500 mg/day for 24 months.
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Eriksson 1997 (Continued)
Group 2: placebo (n = 56).
Outcomes Liver transplantation.
Notes Reasons for post-randomisation dropouts: adverse effects, alcoholic hepatitis, liver trans-
plantation, death
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: placebo used in this double-blind trial; however,
the authors did not state whether the placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: placebo used in this double-blind trial; however,
the authors did not state whether the placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias High risk Quote: “We acknowledge the financial support fromMeda
AB, Searle AB, and the Swedish Medical Research Council
(03x-4793)”
Other bias Low risk Comment: no other source of bias.
Ferri 1993
Methods Randomised clinical trial.
Participants Country: Italy.
Number randomised: 30.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 30.
Mean age: 53 years.
Females: 27 (90%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 6 months
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Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• People with decompensated cirrhosis.
• Extrahepatic biliary obstruction.
• Severe kidney or heart disease.
• Neoplasms.
• Pregnancy or breastfeeding.
• Excessive alcohol consumption.
Interventions Participants were randomly assigned to 2 groups.
Group 1: TUDCA (moderate) (n = 15).
Further details: TUDCA: 13 mg/day to 15 mg/day for 6 months.
Group 2: UDCA (moderate) (n = 15).
Further details: UDCA: 13 mg/day to 15 mg/day for 6 months.
Outcomes Adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: adverse events, the only outcome of interest re-
ported in this study were available from all randomised par-
ticipants
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
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Gao 2012
Methods Randomised clinical trial.
Participants Country: China.
Number randomised: 79.
Post-randomisation dropouts: not stated.
Revised sample size: 79.
Mean age: 53 years.
Females: 77 (97.5%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Other inclusion criteria
• Only people with Sjogren’s syndrome were included.
Exclusion criteria
• People with decompensated cirrhosis.
• Aged > 70 years.
• Other autoimmune diseases.
Interventions Participants were randomly assigned to 3 groups.
Group 1: UDCA (moderate) (n = 29).
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day; duration: not stated
Group 2: UDCA (moderate) + glucocorticosteroids (n = 37).
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day; duration: not stated + pred-
nisolone: 7.5 mg/day; duration: not stated
Group 3: UDCA (moderate) + azathioprine (n = 13).
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day; duration: not stated + azathio-
prine: 1 mg/kg/day; duration: not stated
Outcomes Adverse events, decompensated liver disease.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available.
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Gao 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
Goddard 1994
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 57.
Post-randomisation dropouts: not stated.
Revised sample size: 57.
Mean age: not stated.
Females: not stated.
Symptomatic participants: 30 (52.6%).
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): 15 months.
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 4 groups.
Group 1: UDCA (low) (n = not stated).
Further details: UDCA: 10 mg/kg/day; duration: not stated.
Group 2: colchicine (n = not stated).
Further details: colchicine: 1 mg/day; duration: not stated.
Group 3: UDCA (low) + colchicine (n = not stated).
Further details: UDCA: 10 mg/kg/day; duration: not stated + colchicine: 1 mg/day;
duration: not stated
Group 4: placebo (n = not stated).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
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Goddard 1994 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: placeboused; however, the authors did notmen-
tion blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: placeboused; however, the authors did notmen-
tion blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
Gonzalezkoch 1997
Methods Randomised clinical trial.
Participants Country: Chile.
Number randomised: 25.
Post-randomisation dropouts: not stated.
Revised sample size: 25.
Mean age: 50 years.
Females: 25 (100%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 11 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Other concomitant liver or biliary diseases.
• Decompensated cirrhosis.
• Presence of other serious diseases (e.g. diabetes mellitus, chronic renal
insufficiency).
• Need to use additional medications.
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Gonzalezkoch 1997 (Continued)
• Pregnancy.
• Any pharmacological therapy during the previous 6 months.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) + methotrexate (n = 13).
Further details: UDCA: 250 mg BD for 48 weeks + methotrexate: 10 mg/week given
over 48 hours each week for 48 months
Group 2: UDCA (low) (n = 12).
Further details: UDCA: 250 mg BD for 48 weeks.
Outcomes Mortality, adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Low risk Quote: “A physician who was blinded to the treatment,
followed them up clinically, evaluated clinical symptoms,
adverse side effects, complications and compliance”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: placebo used in this double-blind trial; however,
the authors did not state whether the placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: placebo used in this double-blind trial; however,
the authors did not state whether the placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
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Heathcote 1976
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 45.
Post-randomisation dropouts: 6 (13.3%).
Revised sample size: 39.
Mean age: 51 years.
Females: not stated.
Symptomatic participants: 39 (100%).
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: symptomatic participants only.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Established cirrhosis or liver failure.
• Presence of oesophageal varices.
• Recurrent suppurative infections.
• Treatment with other immunosuppressants.
Interventions Participants were randomly assigned to 2 groups.
Group 1: azathioprine (n = 19).
Further details: azathioprine: 2 mg/kg; frequency and duration: not stated
Group 2: control (n = 20).
Outcomes Mortality, cirrhosis.
Notes Reasons for post-randomisation dropouts: adverse events, wrong diagnosis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomly allocated to the treatment
or control group, using the sealed envelope technique”
Comment: further details of sealed envelope technique not
available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “No placebo was given to the control patients”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “No placebo was given to the control patients”.
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Heathcote 1976 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
For-profit bias Low risk Quote: “This work was supported by the Medical Research
Council and the Ingram Fund”
Other bias Low risk Comment: no other source of bias.
Heathcote 1994
Methods Randomised clinical trial.
Participants Country: Canada.
Number randomised: 222.
Post-randomisation dropouts: not stated.
Revised sample size: 222.
Mean age: 56 years.
Females: 206 (92.8%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 24 months
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Aged < 18 years.
• On transplant list.
• Needed to take enzyme-inducing drugs.
• Pregnant.
• Other medical illnesses with anticipated life expectancy < 5 years.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) (n = 111).
Further details: UDCA: 14 mg/kg/day for 2 years.
Group 2: placebo (n = 111).
Outcomes Mortality, liver transplantation.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Heathcote 1994 (Continued)
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Low risk Quote: “Randomization was done separately at each centre
by the study pharmacist using consecutive identification
numbers, and patients were stratified according to whether
they were symptomatic or asymptomatic”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Once informed consent was obtained from the pa-
tients, double-blind randomization to UDCA or an iden-
tical placebo (1 : 1) was conducted”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Once informed consent was obtained from the pa-
tients, double-blind randomization to UDCA or an iden-
tical placebo (1 : 1) was conducted”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: unclear whether the authors have reported the
outcomes on all randomised participants
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
For-profit bias High risk Quote: “Study medications kindly provided by Interfalk
Canada and Jouveinal Inc., Quebec, Canada”
Other bias Low risk Comment: no other source of bias.
Hendrickse 1999
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 60.
Post-randomisation dropouts: not stated.
Revised sample size: 60.
Mean age: 57 years.
Females: 55 (91.7%).
Symptomatic participants: 57 (95%).
AMA positive: 51 (85%).
Responders: not stated.
Mean follow-up period (for all groups): minimum 68 months.
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• Advanced liver disease.
• Continuing or recent alcohol abuse.
• Immunosuppressive drugs in the previous 6 months.
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Hendrickse 1999 (Continued)
• Contemplation of pregnancy.
• Haematological abnormalities.
• Other serious medical illness that might cause liver dysfunction or limit life
expectancy.
Interventions Participants were randomly assigned to 2 groups.
Group 1: methotrexate (n = 30).
Further details: methotrexate: 2.5 mg 3 times weekly for 6 years
Group 2: placebo (n = 30).
Further details: placebo: 3 times weekly for 6 years.
Outcomes Mortality, liver transplantation.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomized in groups of 10 by a
random-number technique, operated by the hospital phar-
macy, to receive 2.5 mg MTX [methotrexate] or identical
placebo tablets, both supplied by Lederle Laboratories, on
Friday, Saturday, and Sunday of each week for up to 6 years”
Allocation concealment (selection bias) Low risk Quote: “Patients were randomized in groups of 10 by a
random-number technique, operated by the hospital phar-
macy, to receive 2.5 mg MTX or identical placebo tablets,
both supplied by Lederle Laboratories, on Friday, Saturday,
and Sunday of each week for up to 6 years”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: placebo used in this double-blind trial; however,
the authors did not state whether the placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: placebo used in this double-blind trial; however,
the authors did not state whether the placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor morbidity reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
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Hirschfield 2015
Methods Randomised clinical trial.
Participants Country: multicentric; international.
Number randomised: 165.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 165.
Mean age: 55 years.
Females: 157 (95.2%).
Symptomatic participants: not stated.
AMA positive: 134 (81.2%).
Responders: 0 (0%).
Mean follow-up period (for all groups): all participants followed up for 3 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: non-responders only.
Exclusion criteria
• Advanced liver disease or decompensated liver disease.
• Immunosuppressive drugs in the previous 3 months.
• Other concomitant liver diseases.
Interventions Participants were randomly assigned to 3 groups.
Group 1: obeticholic acid (low) (n = 38).
Further details: obeticholic acid (low): 10 mg for 85 days; frequency not stated
Group 2: obeticholic acid (moderate) (n = 48).
Further details: obeticholic acid (moderate): 25 mg for 85 days; frequency not stated
Group 3: obeticholic acid (high) (n = 41).
Further details: obeticholic acid (high): 50 mg for 85 days; frequency not stated
Group 4: placebo (n = 38).
Outcomes Adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The computerized randomization schedule used a
block size of 4 at each center”
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias Unclear risk Comment: information not available.
Other bias High risk Quote: “Patients received varying doses of UDCA”.
Hoofnagle 1986
Methods Randomised clinical trial.
Participants Country: multicentric; international.
Number randomised: 24.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 24.
Mean age: 47 years.
Females: 23 (95.8%).
Symptomatic participants: 24 (100%).
AMA positive: 22 (91.7%).
Responders: not stated.
Mean follow-up period (for all groups): 52 months.
Inclusion criteria
• Symptom status: symptomatic participants only.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• Advanced liver disease or decompensated liver disease.
Interventions Participants were randomly assigned to 2 groups.
Group 1: chlorambucil (n = 13).
Further details: chlorambucil: 2 mg OD; duration: not stated
Group 2: control (n = 11).
Outcomes Mortality, adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomized by random numbers
(generated by pharmacy) to either chlorambucil or no ther-
apy. Pre-computer age. They were kept in envelopes” (au-
thor’s reply)
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Allocation concealment (selection bias) Low risk Quote: “Patients were randomized by random numbers
(generated by pharmacy) to either chlorambucil or no ther-
apy. Pre-computer age. They were kept in envelopes” (au-
thor’s reply)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Not a blinded study” (author’s reply).
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The outcomes were not blinded” (author’s reply).
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias Low risk Quote: “The study was funded by the NIH intramural pro-
gram” (author’s reply)
Other bias Low risk Comment: no other source of bias.
Hosonuma 2015
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 27.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 27.
Mean age: 64 years.
Females: 22 (81.5%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: 0 (0%).
Mean follow-up period (for all groups): minimum: 96 months.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: non-responders only.
Other inclusion criteria
• People with dyslipidaemia.
Exclusion criteria
• Other liver diseases, e.g. alcoholic liver disease.
• Obstructive biliary disease.
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Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) + bezafibrate (n = 13).
Further details: UDCA: 12 mg/kg/day to 15 mg/kg/day; duration: not stated + bezafi-
brate: 400 mg/day; duration: not stated
Group 2: UDCA (moderate) (n = 14).
Further details: UDCA: 12 mg/kg/day to 15 mg/kg/day; duration: not stated
Outcomes Mortality, adverse events, liver transplantation.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Sealed opaque envelopes” (author’s reply).
Allocation concealment (selection bias) Low risk Quote: “These patients were randomly allocated to treat-
ment with either UDCA alone (the UDCA group) or
with the combination therapy (theUDCA+BF [bezafibrate]
group), according to sequential sealed envelopes in blocks
of four to ensure equal randomization for the duration of
the study”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “However, our study was an unblinded, open trial
and was therefore not free from bias”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “However, our study was an unblinded, open trial
and was therefore not free from bias”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events reported.
For-profit bias Low risk Quote: “This study was supported by the authors’ own re-
search funds”
Other bias Low risk Comment: no other source of bias.
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Ikeda 1996
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 22.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 22.
Mean age: 61 years.
Females: 19 (86.4%).
Symptomatic participants: 7 (31.8%).
AMA positive: 22 (100%).
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 24 months
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: AMA-positive participants only.
• Response status: not stated.
Exclusion criteria
• Other liver diseases.
• No immunosuppressants or hepatotoxic drugs in the previous 6 months.
• Alcohol or drug abuse.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) + colchicine (n = 10).
Further details: UDCA: 9 mg/kg/day to 15 mg/kg/day for 2 years + colchicine: 1 mg/
day for 2 years
Group 2: UDCA (moderate) (n = 12).
Further details: UDCA: 9 mg/kg/day to 15 mg/kg/day for 2 years
Outcomes Adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias Unclear risk Quote: “Part of the present study was supported by a grant
from the Intractable Liver Diseases Research Committee,
the Ministry of Health and Welfare, Japan”
Comment: unclear how the remaining part of the funds
were obtained
Other bias High risk Comment: dose range for UDCA was very wide.
Iwasaki 2008a
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 45.
Post-randomisation dropouts: not stated.
Revised sample size: 45.
Mean age: 56 years.
Females: 37 (82.2%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 12 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Cirrhosis.
• Advanced liver disease or decompensated cirrhosis.
• Renal insufficiency.
• Malignancy.
• Pregnancy.
• Aged < 19 years.
Interventions Participants were randomly assigned to 2 groups.
Group 1: bezafibrate (n = 20).
Further details: bezafibrate: 400 mg/day for 52 weeks.
Group 2: UDCA (low) (n = 25).
Further details: UDCA: 600 mg/day for 52 weeks.
Outcomes None of the outcomes of interest reported.
Notes
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Low risk Quote: “Consecutive patients from these hospitalswere ran-
domized centrally at the Kanagawa Dental University and
were enrolled into the study if they met the following cri-
teria”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “A randomized, open study design was used because
there was no suitable placebo for bezafibrate available”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “A randomized, open study design was used because
there was no suitable placebo for bezafibrate available”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Low risk Quote: “The Ministry of Health, Labour and Welfare of
Japan supported this study from2002 to2004with aHealth
Science Research Grant on a Specific Disease (Study of In-
tractable Liver Diseases) to chief scientist Gotaro Toda”
Other bias Low risk Comment: no other bias.
Iwasaki 2008b
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 22.
Post-randomisation dropouts: not stated.
Revised sample size: 22.
Mean age: 54 years.
Females: 19 (86.4%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: 0 (0%).
Mean follow-up period (for all groups): all participants followed up for 12 months
Inclusion criteria
• Symptom status: not stated.
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• AMA status: not stated.
• Response status: non-responders only.
Exclusion criteria
• Cirrhosis.
• Advanced liver disease or decompensated cirrhosis.
• Renal insufficiency.
• Malignancy.
• Pregnancy.
• Aged < 19 years.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) + bezafibrate (n = 10).
Further details: UDCA: 600 mg/day for 52 weeks + bezafibrate: 400 mg/day for 52
weeks
Group 2: UDCA (low) (n = 12).
Further details: UDCA: 600 mg/day for 52 weeks.
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Low risk Quote: “Consecutive patients from these hospitalswere ran-
domized centrally at the Kanagawa Dental University and
were enrolled into the study if they met the following cri-
teria”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “A randomized, open study design was used because
there was no suitable placebo for bezafibrate available”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “A randomized, open study design was used because
there was no suitable placebo for bezafibrate available”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Low risk Quote: “The Ministry of Health, Labour and Welfare of
Japan supported this study from2002 to2004with aHealth
Science Research Grant on a Specific Disease (Study of In-
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tractable Liver Diseases) to chief scientist Gotaro Toda”
Other bias Low risk Comment: no other bias.
Kanda 2003
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 22.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 22.
Mean age: 56 years.
Females: 19 (86.4%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: 0 (0%).
Mean follow-up period (for all groups): minimum 7 months.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: non-responders only.
Other inclusion criteria
• Treatment with UDCA for ≥ 6 months prior the study.
• Prior compliance with UDCA therapy.
Exclusion criteria
• Other chronic liver diseases or decompensated liver disease.
• Previous colchicine, corticosteroid, or immunosuppressive treatment.
• Thyroid or renal dysfunction.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) + bezafibrate (n = 11).
Further details: UDCA: 600 mg/day for 6 months + bezafibrate: 400 mg/day for 52
weeks
Group 2: UDCA (low) (n = 11).
Further details: UDCA: 600 mg/day for 6 months.
Outcomes Adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality was not reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other bias.
Kaplan 1986
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 60.
Post-randomisation dropouts: 3 (5%).
Revised sample size: 57.
Mean age: not stated.
Females: 57 (100%).
Symptomatic participants: 45 (78.9%).
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 24 months
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• Concomitant debilitating cardiovascular illness.
• End-stage cirrhosis.
Interventions Participants were randomly assigned to 2 groups.
Group 1: colchicine (n = 28).
Further details: colchicine: 0.6 mg BD for ≥ 2 years.
Group 2: placebo (n = 29).
Outcomes Mortality.
Notes Reasons for post-randomisation dropouts: adverse effects, despondent about treatment
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: authors stated that this was a double-blind trial
and used a placebo; however, they did not state whether the
placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: authors stated that this was a double-blind trial
and used a placebo; however, they did not state whether the
placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other bias.
Kaplan 1999
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 87.
Post-randomisation dropouts: 2 (2.3%).
Revised sample size: 85.
Mean age: 51 years.
Females: 82 (96.5%).
Symptomatic participants: 71 (83.5%).
AMA positive: 77 (90.6%).
Responders: not stated.
Mean follow-up period (for all groups): minimum 24 months.
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• End-stage liver failure.
• History of alcohol abuse.
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• Administration of drugs associated with chronic liver disease.
• Contemplation of pregnancy.
• Other serious medical illnesses such as renal or heart disease that may cause liver
dysfunction or shorten life expectancy.
• Hypersplenism.
Interventions Participants were randomly assigned to 2 groups.
Group 1: colchicine (n = 43).
Further details: colchicine: 0.6 mg BD for 2 years.
Group 2: methotrexate (n = 42).
Further details: methotrexate: 15 mg/week orally.
Outcomes None of the outcomes of interest reported.
Notes Reasons for post-randomisation dropouts: withdrawal from study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both the patients and investigators were blinded
to the treatment assignments”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Both the patients and investigators were blinded
to the treatment assignments”
Comment: authors stated that this was a double-blind trial
and used a placebo; however, they did not state whether the
placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other bias.
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Kowdley 2011
Methods Randomised clinical trial.
Participants Country: multicentric; international.
Number randomised: 59.
Post-randomisation dropouts: not stated.
Revised sample size: 59.
Mean age: 55 years.
Females: 50 (84.7%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 3 groups.
Group 1: obeticholic acid (low) (n = 20).
Further details: obeticholic acid (low): 10 mg OD for 12 weeks
Group 2: obeticholic acid (high) (n = 16).
Further details: obeticholic acid (high): 50 mg OD for 12 weeks
Group 3: placebo (n = 23).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although this was a double-blind trial and
placebowas used, unclear whether the placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although this was a double-blind trial and
placebowas used, unclear whether the placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
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For-profit bias High risk Comment: some of the coauthors were from the pharma-
ceutical industry
Other bias Low risk Comment: no other source of bias.
Kurihara 2000
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 24.
Post-randomisation dropouts: not stated.
Revised sample size: 24.
Mean age: 60 years.
Females: 23 (95.8%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Cirrhosis.
• Advanced liver disease or decompensated cirrhosis.
• Renal insufficiency.
• Malignancy.
• Pregnancy.
• Aged < 19 years of age.
Interventions Participants were randomly assigned to 2 groups.
Group 1: bezafibrate (n = 12).
Further details: bezafibrate: 400 mg/day for 1 year.
Group 2: UDCA (low) (n = 12).
Further details: UDCA: 600 mg/day for 1 year.
Outcomes Adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
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Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other bias.
Leuschner 1989
Methods Randomised clinical trial.
Participants Country: Germany.
Number randomised: 20.
Post-randomisation dropouts: 2 (10%).
Revised sample size: 18.
Mean age: not stated.
Females: 18 (100%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 12 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Decompensated liver cirrhosis.
• Chronic pancreatitis.
• Taking immunosuppressive drugs, glucocorticosteroids, or sex hormones.
• Taking other drugs for treatment of liver diseases or known to cause
hepatotoxicity.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) (n = 10).
Further details: UDCA: 10 mg/kg/day for 9 months.
Group 2: placebo (n = 8).
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Leuschner 1989 (Continued)
Outcomes Mortality, adverse events.
Notes Reasons for post-randomisation dropouts: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although placebo was used in this double-blind
trial, unclear whether identical placebo used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although placebo was used in this double-blind
trial, unclear whether identical placebo used
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
Leuschner 1999
Methods Randomised clinical trial.
Participants Country: Germany.
Number randomised: 40.
Post-randomisation dropouts: 1 (2.5%).
Revised sample size: 39.
Mean age: 58 years.
Females: 37 (94.9%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 24 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
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Exclusion criteria
• Decompensated liver cirrhosis.
• Diabetes mellitus.
• Glaucoma.
• Previous history of duodenal or gastric ulcer.
• Pregnancy.
• Hypertension.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) + corticosteroids (n = 20).
Further details: UDCA: 10 mg/kg/day to 15 mg/kg/day for 2 years + budesonide: 3 mg
3 times daily for 2 years
Group 2: UDCA (moderate) (n = 19).
Outcomes None of the outcomes of interest reported.
Notes Reasons for post-randomisation dropouts: personal reasons.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Complete randomization was done according to
Rancode + (version 3.1; IDV-Co., Marsaglia and Bray,
Gauting, Germany)”
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although placebo was used in this double-blind
trial, unclear whether identical placebo used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although placebo was used in this double-blind
trial, unclear whether identical placebo used
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias High risk Quote: “UDCA, budesonide, and placebo were provided
by Dr. Falk Pharma GmbH (Freiburg, Germany)”
Other bias Low risk Comment: no other source of bias.
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Liberopoulos 2010
Methods Randomised clinical trial.
Participants Country: Greece.
Number randomised: 10.
Post-randomisation dropouts: not stated.
Revised sample size: 10.
Mean age: 57 years.
Females: 8 (80%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: 0 (0%).
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: non-responders only.
Exclusion criteria
• Cardiovascular disease.
• Diabetes mellitus.
• Cancer.
• Renal disease.
• Hypothyroidism.
• Recent lipid-lowering agent use.
• Agents that affect lipid metabolism.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) + fenofibrate (n = 6).
Further details: UDCA: 600 mg/day for 8 weeks + fenofibrate: 200 mg/day for 8 weeks
Group 2: UDCA (low) (n = 4).
Further details: UDCA: 600 mg/day for 8 weeks.
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Continue open-label UDCA”.
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Continue open-label UDCA”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Quote: “This study was conducted independently; no com-
pany or institution supported it financially. Some of the
authors have given talks, attended conferences and partic-
ipated in trials and advisory boards sponsored by various
pharmaceutical companies”.
Comment: unclearwhether the authorswere in the advisory
board of related pharmaceutical companies
Other bias Low risk Comment: no other source of bias.
Lim 1994
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 32.
Post-randomisation dropouts: not stated.
Revised sample size: 32.
Mean age: not stated.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) (n = not stated).
Further details: UDCA: 10 mg/kg/day to 12 mg/kg/day; duration: not stated
Group 2: placebo (n = not stated).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although a placebo was used in this double-
blind trial, unclear whether the placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebo was used in this double-
blind trial, unclear whether the placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
Lindor 1994
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 180.
Post-randomisation dropouts: 10 (5.6%).
Revised sample size: 170.
Mean age: 53 years.
Females: 160 (94.1%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 24 months
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• People with decompensated cirrhosis.
• Hepatocellular carcinoma.
• Concomitant immunosuppressive regimen.
• Other major diseases unrelated to primary biliary cholangitis.
• Alcohol abuse.
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• Low compliance.
• Recurrent variceal haemorrhage, intractable ascites, spontaneous encephalopathy.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) (n = 86).
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day; duration: not stated
Group 2: placebo (n = 84).
Outcomes Mortality, adverse events, liver transplantation.
Notes Reasons for post-randomisation dropouts: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patients, physicians, nurses, and study coor-
dinators were blinded as to whether active drug or placebo
was being administered”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The patients, physicians, nurses, and study coor-
dinators were blinded as to whether active drug or placebo
was being administered”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias High risk Quote: “Supported by Falk Pharma and Interfalk”.
Other bias Low risk Comment: no other risk of bias.
Lindor 1997
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 150.
Post-randomisation dropouts: not stated.
Revised sample size: 150.
Mean age: not stated.
Females: not stated.
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Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 12 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: AMA positive participants only.
• Response status: not stated.
Interventions Participants were randomly assigned to 3 groups.
Group 1: UDCA (low) (n = not stated).
Further details: UDCA: 5 mg/kg/day to 7 mg/kg/day; duration: not stated
Group 2: UDCA (moderate) (n = not stated).
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day; duration: not stated
Group 3: UDCA (high) (n = not stated).
Further details: UDCA: 22 mg/kg/day to 25 mg/kg/day; duration: not stated
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other risk of bias.
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Lombard 1993
Methods Randomised clinical trial.
Participants Country: multicentric; international.
Number randomised: 349.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 349.
Mean age: 54 years.
Females: 298 (85.4%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Median follow-up period (for all groups): 31 months.
Inclusion criteria
• Symptom status: not stated.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• Significant renal impairment.
• Serious non-hepatic or malignant disease limiting life expectancy.
• Inability to attend for regular follow-up.
• Consideration for a liver transplant.
Interventions Participants were randomly assigned to 2 groups.
Group 1: ciclosporin (n = 176).
Further details: ciclosporin: 3 mg/kg/day to maintain levels at 150 ng/mL by polyclonal
radioimmunoassay or 75 ng/mL by monoclonal radioimmunoassay
Group 2: placebo (n = 173).
Outcomes Mortality, adverse events, liver transplantation.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Quote: “Sealed envelopes” (author’s reply).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias High risk Quote: “The authors are grateful to Sandoz Pharmaceuti-
cals, Basle, Switzerland and their international sub-offices
for supplying Sandimmune and placebo for this study and
for their support throughout. The authors are grateful to
Sandoz Pharmaceuticals, Basle, Zerland and their interna-
tional sub-offices for supplying Sandimmune and placebo
for this study and for their support throughout”
Other bias Low risk Comment: no other source of bias.
Ma 2016
Methods Randomised clinical trial.
Participants Country: China.
Number randomised: 199.
Post-randomisation dropouts: 8 (4.0%).
Revised sample size: 191.
Mean age: 51 years.
Females: 167 (83.9%).
Symptomatic participants: 38 (19.9%).
AMA positive: 187 (97.9%).
Responders: not stated.
Mean follow-up period (for all groups): all participants: 6 months
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• Advanced or decompensated liver disease.
• Pregnancy or breastfeeding.
• Other causes of liver diseases.
• Serious comorbidities.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) (n = 66).
Further details: UDCA: 250 mg 3 times daily for 24 weeks.
Group 2: TUDCA (moderate) (n = 125).
Further details: TUDCA: 250 mg 3 times daily for 24 weeks.
Outcomes Adverse events.
Notes Reason for drop-outs: not reported.
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A centralized telecommunication-based interactive
voice response system was used for patient randomization
after patient eligibility was determined through clinical and
laboratory screening assessments”
Allocation concealment (selection bias) Low risk Quote: “A centralized telecommunication-based interactive
voice response system was used for patient randomization
after patient eligibility was determined through clinical and
laboratory screening assessments”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: unclear whether all participants were included
in the analysis
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias High risk Quote: “This study was sponsored by the Beijing Trendful
Kangjian Medical Information Consulting Co., Ltd. and
theMajor Science and Technology Special Project of China
Twelfth Five-year Plan (2012ZX10002003). Registration
Number: NCT01829698”
Other bias Low risk Comment: no other source of bias.
Macklon 1982
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 60.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 60.
Mean age: not stated.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
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Mean follow-up period (for all groups): 37 months.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: D-penicillamine (n = 41).
Further details: D-penicillamine: 250 mg/day or 1 g/day; duration: not stated
Group 2: placebo (n = 19).
Outcomes Mortality, adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although placebo was used, there is no mention
of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although placebo was used, there is no mention
of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other bias.
Manzillo 1993a
Methods Randomised clinical trial.
Participants Country: Italy.
Number randomised: 32.
Post-randomisation dropouts: not stated.
Revised sample size: 32.
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Mean age: not stated.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 1 month
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: SAMe (n = 16).
Further details: SAMe: 800 mg/day IV for 2 weeks.
Group 2: placebo (n = 16).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although placebo was used, there was no men-
tion of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although placebo was used, there was no men-
tion of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other bias.
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Manzillo 1993b
Methods Randomised clinical trial.
Participants Country: Italy.
Number randomised: 6.
Post-randomisation dropouts: not stated.
Revised sample size: 6.
Mean age: not stated.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 2 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: SAMe (n = 3).
Further details: SAMe: 1600 mg/day orally for 8 weeks.
Group 2: placebo (n = 3).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although placebo was used, there was no men-
tion of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although placebo was used, there was no men-
tion of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
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Other bias Low risk Comment: no other bias.
Mason 2008
Methods Randomised clinical trial.
Participants Country: multicentric; international.
Number randomised: 59.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 59.
Mean age: 56 years.
Females: 58 (98.3%).
Symptomatic participants: not stated.
AMA positive: 59 (100%).
Responders: 0 (0%).
Mean follow-up period (for all groups): all participants followed up for 6 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: AMA-positive participants only.
• Response status: non-responders only.
Other exclusion criteria
• Advanced or decompensated liver disease.
• Use of immunosuppressants or anti-inflammatory drugs in previous 3 months.
• Significant renal impairment.
• Excessive alcohol consumption.
• Pregnant, breastfeeding, or not using contraceptives in sexually active women of
child-bearing age.
Interventions Participants were randomly assigned to 2 groups.
Group 1: lamivudine + zidovudine + UDCA (moderate) (n = 30).
Further details: lamivudine: 150 mg BD for 6 months + zidovudine: 300 mg BD for 6
months + UDCA: 13 mg/kg/day to 15 mg/kg/day for 6 months
Group 2: UDCA (moderate) (n = 29).
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day for 6 months
Outcomes Adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was performed centrally at the
University of Alberta by a dynamic randomization” (au-
thor’s reply)
Allocation concealment (selection bias) Low risk Quote: “Sealed opaque envelopes” (author’s reply).
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Mason 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Dilan Clinical Packaging Ltd (Mississauga, ON,
Canada) coded samples ensuring that the investigators and
patients were blinded to the treatment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Dilan Clinical Packaging Ltd (Mississauga, ON,
Canada) coded samples ensuring that the investigators and
patients were blinded to the treatment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias High risk Quote: “This study was funded in full by GlaxoSmithKline
and Axcan Pharma”
Other bias Low risk Comment: no other bias.
Matloff 1982
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 52.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 52.
Mean age: 52 years.
Females: 48 (92.3%).
Symptomatic participants: not stated.
AMA positive: 42 (80.8%).
Responders: not stated.
Mean follow-up period (for all groups): minimum 24 months.
Inclusion criteria
• Symptom status: not stated.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: D-penicillamine (n = 26).
Further details: D-penicillamine: 1 g/day; duration: not stated
Group 2: placebo (n = 26).
Outcomes Mortality, adverse events.
Notes
Risk of bias Risk of bias
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Matloff 1982 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although placebo was used in this double-blind
trial, there was no mention about identical placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although placebo was used in this double-blind
trial, there was no mention about identical placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias High risk Quote: “We are indebted to Merck, Sharp and Dohme Re-
search Laboratories for providing the D-penicillamine and
placebo tablets”
Other bias Low risk Comment: no other bias.
Mayo 2015
Methods Randomised clinical trial.
Participants Country: multicentric; international.
Number randomised: 45.
Post-randomisation dropouts: 3 (6.7%).
Revised sample size: 42.
Mean age: 56 years.
Females: 38 (90.5%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: NGM282 (n = 27).
Further details: NGM282: 0.3 mg/day or 3 mg/day SC for 28 days
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Mayo 2015 (Continued)
Group 2: placebo (n = 15).
Outcomes None of the outcomes of interest reported.
Notes Reasons for post-randomisation dropouts: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although placebo was used in this double-blind
trial, unclear whether the placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although placebo was used in this double-blind
trial, unclear whether the placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias High risk Quote: “Grant/Research Support: Intercept, Salix, NGM,
Lumena, Gilead”
Other bias Low risk Comment: no other bias.
Mazzarella 2002
Methods Randomised clinical trial.
Participants Country: Italy.
Number randomised: 42.
Post-randomisation dropouts: not stated.
Revised sample size: 42.
Mean age: not stated.
Females: 37 (88.1%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 72 months
Inclusion criteria
• Symptom status: not stated.
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Mazzarella 2002 (Continued)
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (high) (n = 21).
Further details: UDCA (high): 30 mg/kg/day for 6 years.
Group 2: UDCA (moderate) (n = 21).
Further details: UDCA (moderate): 10.5 mg/kg/day for 6 years
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other bias.
McCormick 1994
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 18.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 18.
Mean age: 60 years.
Females: 14 (77.8%).
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McCormick 1994 (Continued)
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Premenopausal or unsterilised women.
Interventions Participants were randomly assigned to 2 groups.
Group 1: thalidomide (n = 10).
Further details: thalidomide: 100 mg/day for 6 months.
Group 2: placebo (n = 8).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias High risk Quote: “Thalidomide and identical placebo tablets were
supplied by Penn Pharmaceuticals Ltd”
Other bias Low risk Comment: no other bias.
120Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Minuk 1988
Methods Randomised clinical trial.
Participants Country: Canada.
Number randomised: 12.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 12.
Mean age: 55 years.
Females: 11 (91.7%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: ciclosporin (n = 6).
Further details: ciclosporin: maintain serum radioimmunoassay dosage between 100 ng/
mL and 200 ng/mL for 12 months
Group 2: placebo (n = 6).
Outcomes Mortality, adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Quote: “…patients were randomized by sealed envelope to
receive either cyclosporin A or placebo”.
Comment: further details of the sealed envelope method
not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebo was used, there was no men-
tion about blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: although a placebo was used, there was no men-
tion about blinding
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Minuk 1988 (Continued)
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias High risk Comment: the drugs were provided by the pharmaceutical
company
Other bias Low risk Comment: no other bias.
Mitchison 1989
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 36.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 36.
Mean age: 55 years.
Females: 33 (91.7%).
Symptomatic participants: 35 (97.2%).
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 36 months
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Aged > 70 years.
• Treatment for primary biliary cirrhosis in the preceding 4 months.
• Early liver disease.
Interventions Participants were randomly assigned to 2 groups.
Group 1: glucocorticosteroids (n = 19).
Further details: prednisolone: 10 mg/day for 36 months (loading dose was used)
Group 2: placebo (n = 17).
Outcomes Mortality.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were paired according to the presence or
absence of cirrhosis, their age by decade, menopausal status
(for women) and their serum bilirubin (greater or less than
30 µmoles per litre)”
Comment: minimisation used.
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Mitchison 1989 (Continued)
Allocation concealment (selection bias) Low risk Quote: “Patients were paired according to the presence or
absence of cirrhosis, their age by decade, menopausal status
(for women) and their serum bilirubin (greater or less than
30 µmoles per litre)”
Comment: minimisation used.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Study was double-blind for the first year, single
blind thereafter (patients were blinded)”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Study was double-blind for the first year, single
blind thereafter (patients were blinded)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other bias.
Mitchison 1993
Methods Randomised clinical trial.
Participants Country: multicentric; international.
Number randomised: 104.
Post-randomisation dropouts: 3 (2.9%).
Revised sample size: 101.
Mean age: 54 years.
Females: 93 (92.1%).
Symptomatic participants: 101 (100%).
AMA positive: not stated.
Responders: not stated.
Median follow-up period (for all groups): 25 months.
Inclusion criteria
• Symptom status: symptomatic participants only.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Aged > 65 years.
• Immunosuppressive drugs in the preceding 6 months.
• Advanced liver disease or decompensated liver disease.
Interventions Participants were randomly assigned to 2 groups.
Group 1: malotilate (n = 52).
Further details: malotilate: 500 mg 3 times daily; mean duration: 23 months
123Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mitchison 1993 (Continued)
Group 2: placebo (n = 49).
Outcomes Mortality, adverse events.
Notes Reasons for post-randomisation dropouts: elementary data not available
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random sequence was generated by the trial statis-
tician with tables with random numbers” (author’s reply)
Allocation concealment (selection bias) Low risk Quote: “Sequentially numbered identical containers” (au-
thor’s reply)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both patients and doctors were unaware of the
nature of the tablets”.
Comment: placebo used to achieve blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Both patients and doctors were unaware of the
nature of the tablets”.
Comment: placebo used to achieve blinding.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias High risk Quote: “The study was supported in part by Zyma S.A.,
Nyon, Switzerland, and by Nihon Nohyaku, Tokyo, Japan”
Other bias Low risk Comment: no other source of bias.
Nakai 2000
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 23.
Post-randomisation dropouts: not stated.
Revised sample size: 23.
Mean age: 57 years.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 12 months
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Nakai 2000 (Continued)
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) + bezafibrate (n = 13).
Further details: UDCA: 600 mg/day; duration: not stated + bezafibrate: 400 mg/day;
duration: not stated
Group 2: UDCA (low) (n = 10).
Further details: UDCA: 600 mg/day; duration: not stated.
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Low risk Quote: “This work was supported by a Grant-in-Aid for
Scientific Research from theMinistry of Education, Science
and Culture of Japan”
Other bias Low risk Comment: no other source of bias.
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Neuberger 1985
Methods Randomised clinical trial.
Participants Country: multicentric; international.
Number randomised: 189.
Post-randomisation dropouts: not stated.
Revised sample size: 189.
Mean age: not stated.
Females: 174 (92.1%).
Symptomatic participants: 172 (91%).
AMA positive: 163 (86.2%).
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• Taking azathioprine in the previous 6 months.
Interventions Participants were randomly assigned to 2 groups.
Group 1: D-penicillamine (n = 98).
Further details: D-penicillamine: 1200 mg/day; duration: not stated
Group 2: placebo (n = 91).
Outcomes Mortality, liver transplantation.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Low risk Quote: “Opaque sealed envelopes” (author’s reply).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Double blind trial, identical appearing placebo”
(author’s reply)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Assessors were blinded, identical placebo” (author’s
reply)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
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Neuberger 1985 (Continued)
For-profit bias Unclear risk Quote: “Not pharmaceutical funding” (author’s reply).
Other bias Low risk Comment: no other source of bias.
Nevens 2016
Methods Randomised clinical trial.
Participants Country: multicentric; international.
Number randomised: 217.
Post-randomisation dropouts: 1.
Revised sample size: 216.
Mean age: 56 years.
Females: 196 (90.7%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: 0 (0%).
Mean follow-up period (for all groups): all participants followed up for 12 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: non-responders only.
• Aged > 18 years.
• Alkaline phosphatase level≥ 1.67 times the upper limit of the normal range or an
abnormal total bilirubin level < 2 times the upper limit of the normal range.
Interventions Participants were randomly assigned to 2 groups.
Group 1: obeticholic acid (low) + UDCA (moderate) (n = 143).
Further details: obeticholic acid: 5 mg to 10 mg for 1 year + UDCA: 13 mg/kg/day to
15 mg/kg/day for 1 year
Group 2: UDCA (moderate) (n = 73).
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day for 1 year
Outcomes Mortality, adverse events.
Notes Reasons for post-randomisation dropouts: withdrawal from study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “On a predefined randomization code (generated
by the Sponsor or designee) using an IWRS”
Allocation concealment (selection bias) Low risk Quote: “The randomization number will be recorded in the
CRF and will serve for patient identification and for assign-
ment of appropriate study medication and bottle number
(s) by the IWRS”
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Nevens 2016 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used and authors stated dou-
ble-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used and authors stated dou-
ble-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias High risk Quote: “Supported by Intercept Pharmaceuticals”.
Comment: trial funded by industrial sources which might
benefit by the nature of the results
Other bias Low risk Comment: no other source of bias.
Oka 1990
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 52.
Post-randomisation dropouts: 7 (13.5%).
Revised sample size: 45.
Mean age: 59 years.
Females: 41 (91.1%).
Symptomatic participants: 17 (37.8%).
AMA positive: 41 (91.1%).
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: symptomatic and asymptomatic participants.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• Advanced liver disease or decompensated liver disease.
• Pregnancy.
• Complications from illnesses other than primary biliary cholangitis.
• Use of treatment for primary biliary cholangitis within the past 3 months.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) (n = 22).
Further details: UDCA: 600 mg/day for 24 weeks.
Group 2: placebo (n = 23).
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Oka 1990 (Continued)
Outcomes None of the outcomes of interest reported.
Notes Reasons for post-randomisation dropouts: worsening liver disease, lack of compliance
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Low risk Quote: “The patients were allocated to two groups, a
UDCA group and a placebo group, by a single monitor ac-
cording to a randomization scheme in which the number
of patients allocated to two groups tended to be equal”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias High risk Quote: “UDCA and placebo tablets were generously fur-
nished by Tokyo Tanabe Pharmaceutical Company”
Other bias Low risk Comment: no other source of bias.
Papatheodoridis 2002
Methods Randomised clinical trial.
Participants Country: Greece.
Number randomised: 92.
Post-randomisation dropouts: 6 (6.5%).
Revised sample size: 86.
Mean age: 54 years.
Females: 77 (89.5%).
Symptomatic participants: 86 (100%).
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): 89 months.
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Papatheodoridis 2002 (Continued)
Inclusion criteria
• Symptom status: symptomatic participants only.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Extrahepatic biliary obstruction.
• Other liver diseases.
• Aged > 70 years.
• Immunosuppression within previous 12 months.
• Advanced or decompensated liver disease.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) (n = 43).
Further details: UDCA: 12 mg/kg//day to 15 mg/kg//day for ≥ 2 years
Group 2: control (n = 43).
Outcomes Mortality, liver transplantation, decompensated liver disease
Notes Reasons for post-randomisation dropouts: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was carried out by serially num-
bered sealed envelopes containing random table numbers
14 patients crossed over from placebo to UDCA”
Allocation concealment (selection bias) Low risk Quote: “Randomization was carried out by serially num-
bered sealed envelopes containing random table numbers
14 patients crossed over from placebo to UDCA”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Patients andhealthcare providerswere not blinded”
(author’s reply)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The outcome assessors were not blinded” (author’s
reply)
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts in the
initial report
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
For-profit bias High risk Quote: “Support for this work was provided during the first
2 years of the study by a research grant the pharmaceutical
company Galenica Hellas and by the Greek Ministry of
Health and Welfare”
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Papatheodoridis 2002 (Continued)
Other bias High risk Comment: 14 participants crossed over from placebo to
UDCA.
Pares 2000
Methods Randomised clinical trial.
Participants Country: Spain.
Number randomised: 192.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 192.
Mean age: 54 years.
Females: 179 (93.2%).
Symptomatic participants: not stated.
AMA positive: 172 (89.6%).
Responders: not stated.
Median follow-up period (for all groups): 41 months.
Inclusion criteria
• Symptom status: not stated.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• Aged > 72 years.
• Immunosuppression within previous 6 months.
• Life expectancy < 6 months.
• Pregnancy.
• Drug addiction.
• Other liver diseases.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) (n = 99).
Further details: UDCA 14 mg/kg/day to 16 mg/kg/day; duration: 25 to 73 months
Group 2: placebo (n = 93).
Outcomes Mortality, adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
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Pares 2000 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: unclear whether all participants were included
in the analysis
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias High risk Quote: “We are indebted to Zambon S. A., Laboratorio
Farmaceutico for supplying the UDCA and placebo cap-
sules, and for the invaluable administrative support”
Other bias Low risk Comment: no other risk of bias.
Poupon 1991a
Methods Randomised clinical trial.
Participants Country: France.
Number randomised: 149.
Post-randomisation dropouts: 3 (2%).
Revised sample size: 146.
Mean age: 56 years.
Females: 134 (91.8%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Received any of the following drugs during the previous 6 months: ursodiol,
azathioprine, chlorambucil, colchicine, corticosteroids, D-penicillamine, and
ciclosporin.
• Serum bilirubin concentration > 150 µmol/L.
• Serum albumin concentration < 25 g/L.
• Past or active gastrointestinal bleeding from oesophageal varices.
• Evidence of past or present extrahepatic obstruction of the bile ducts.
• Excessive alcohol consumption (> 50 g/day).
• Positive test for hepatitis B surface antigen.
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Poupon 1991a (Continued)
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) (n = 73).
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day for 2 years
Group 2: placebo (n = 73).
Outcomes None of the outcomes of interest reported.
Notes Reasons for post-randomisation dropouts: bilirubin > 300 µmol/L, ascites, other coex-
isting disease
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias High risk Quote: “This work was supported in part by Synthélabo-
Recherche and in Canada by Jouveinal and Interfalk”
Other bias Low risk Comment: no other source of bias.
Poupon 1996
Methods Randomised clinical trial.
Participants Country: France.
Number randomised: 74.
Post-randomisation dropouts: not stated.
Revised sample size: 74.
Mean age: 54 years.
Females: 63 (85.1%).
Symptomatic participants: not stated.
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AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 24 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Received any of the following drugs during the previous 6 months: ursodiol,
azathioprine, chlorambucil, colchicine, corticosteroids, D-penicillamine, and
ciclosporin.
• Serum bilirubin concentration > 150 µmol/L.
• Serum albumin concentration < 25 g/L.
• Past or active gastrointestinal bleeding from oesophageal varices.
• Evidence of past or present extrahepatic obstruction of the bile ducts.
• Excessive alcohol consumption (> 50 g/day).
• Other identified causes of liver or biliary diseases.
• Aged ≥ 75 years.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) + colchicine (n = 37).
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day for 2 years + colchicine: 1 mg/
day for 5 days in a week for 2 years
Group 2: UDCA (moderate) (n = 37).
Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day for 2 years
Outcomes Mortality, adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: unclear whether all randomised participants
were included for analysis
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Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias High risk Quote: “Supported in part by Laboratoires Houde (France)
and Jouveinal (Canada)”
Other bias Low risk Comment: no other source of bias.
Raedsch 1993
Methods Randomised clinical trial.
Participants Country: Germany.
Number randomised: 28.
Post-randomisation dropouts: 8 (28.6%).
Revised sample size: 20.
Mean age: 54 years.
Females: 20 (100%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 24 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) + colchicine (n = 8).
Further details: UDCA: 10 mg/kg/day to 12 mg/kg/day for 24 months + colchicine: 1
mg/day for 24 months
Group 2: UDCA (moderate) (n = 12).
Further details: UDCA: 10 mg/kg/day to 12 mg/kg/day for 24 months
Outcomes Adverse events.
Notes Reasons for post-randomisation dropouts: adverse events, lost to follow-up
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although a placebo used in this double-blind
trial, unclear whether the placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebo used in this double-blind
trial, unclear whether the placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
Rautiainen 2005
Methods Randomised clinical trial.
Participants Country: Finland.
Number randomised: 77.
Post-randomisation dropouts: 8 (10.4%).
Revised sample size: 69.
Mean age: 53 years.
Females: 60 (87%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 36 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Aged < 18 years or > 70 years.
• Pregnancy or inadequate contraceptive use.
• Systemic immunosuppressive use.
• Other liver diseases.
• Cirrhosis.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) + glucocorticosteroids (n = 37).
Further details: UDCA: 15 mg/kg/day for 3 years + budesonide: 6 mg/day for 3 years
Group 2: UDCA (moderate) (n = 32).
Further details: UDCA: 15 mg/kg/day for 3 years.
Outcomes Adverse events.
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Notes Reasons for post-randomisation dropouts: adverse effects, death, refused follow-up
biopsy
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Quote: “Randomization was done centrally at Helsinki
University Hospital with sealed envelopes in a block of 10”
Comment: further details of sealed envelope technique not
available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Study design was randomized but open because
placebo for budesonide was not available for us”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Study design was randomized but open because
placebo for budesonide was not available for us”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias High risk Quote: “Medication was supplied free of charge by As-
traZeneca Finland (budesonide, Entocort) and Leiras Fin-
land (UDCA, Adursal)”
Other bias Low risk Comment: no other source of bias.
Senior 1991
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 20.
Post-randomisation dropouts: 1 (5%).
Revised sample size: 19.
Mean age: not stated.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 18 months
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Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) (n = 9).
Further details: UDCA (low): 8 mg/kg/day to 12 mg/kg/day for 6 months
Group 2: placebo (n = 10).
Outcomes None of the outcomes of interest reported.
Notes Reasons for post-randomisation dropouts: had coexisting gallstones
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although a placebo used in this double-blind
trial, unclear whether the placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebo used in this double-blind
trial, unclear whether the placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias High risk Quote: “andursodiol supplies provided byCiba-GeigyCor-
poration”
Other bias Low risk Comment: no other source of bias.
Smart 1990
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 20.
Post-randomisation dropouts: not stated.
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Revised sample size: 20.
Mean age: not stated.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: antioxidants (n = not stated).
Further details: antioxidant: cocktail of vitamin E 100 mg, zinc 135 mg, and selenium
100 µg daily; duration: not stated
Group 2: placebo (n = not stated).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although a placebo was used, no mention of
blinding made
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebo was used, no mention of
blinding made
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
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Methods Randomised clinical trial.
Participants Country: Belgium.
Number randomised: 14.
Post-randomisation dropouts: not stated.
Revised sample size: 14.
Mean age: 51 years.
Females: 12 (85.7%).
Symptomatic participants: not stated.
AMA positive: 13 (92.9%).
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 24 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: AMA-positive and AMA-negative participants.
• Response status: not stated.
Exclusion criteria
• Presence of cirrhosis.
• Excessive alcohol consumption.
• Other viral diseases.
• Mental disorders.
• Pregnancy.
• Chronic infection.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) + methotrexate (n = 8).
Further details: UDCA: 500 mg/day; duration: not stated + methotrexate: 15 mg/week;
duration: not stated
Group 2: control (n = 6).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Using a random number table…”.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
Taal 1983
Methods Randomised clinical trial.
Participants Country: Netherlands.
Number randomised: 24.
Post-randomisation dropouts: not stated.
Revised sample size: 24.
Mean age: 49 years.
Females: 23 (95.8%).
Symptomatic participants: 24 (100%).
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 18 months
Inclusion criteria
• Symptom status: symptomatic participants only.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Advanced or decompensated liver disease.
• Use of cholestatic drug in the previous 6 months.
• Associated inflammatory bowel disease.
• Neoplasm within last 5 years.
• Pregnancy.
Interventions Participants were randomly assigned to 2 groups.
Group 1: D-penicillamine (n = 11).
Further details: D-penicillamine: 250 mg/day to 1000 mg/day (escalating dose) and then
500 mg/day: total duration: 1 year
Group 2: placebo (n = 13).
Outcomes Mortality, adverse events, decompensated liver disease.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
Triger 1980
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 35.
Post-randomisation dropouts: not stated.
Revised sample size: 35.
Mean age: not stated.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: D-penicillamine (n = not stated).
Further details: D-penicillamine: 250 mg to 875 mg (escalating dose)
Group 2: placebo (n = not stated).
Outcomes Mortality.
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Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: in this double-blind trial, unclear whether the
placebo was identical to active treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: in this double-blind trial, unclear whether the
placebo was identical to active treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
For-profit bias High risk Quote: “The UDCA and placebo tablets were generously
donated by Thames Laboratories, Wrexham, Wales”
Other bias Low risk Comment: no other source of bias.
Turner 1994
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 46.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 46.
Mean age: 58 years.
Females: 44 (95.7%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): all participants followed up for 24 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
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Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) (n = 22).
Further details: UDCA: 10 mg/kg/day for 2 years.
Group 2: placebo (n = 24).
Outcomes Mortality, liver transplantation, cirrhosis.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: adverse events not reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
Ueno 2005
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 20.
Post-randomisation dropouts: not stated.
Revised sample size: 20.
Mean age: not stated.
Females: 16 (80%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: 0 (0%).
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Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: non-responders only
Exclusion criteria
• Aged < 20 years or > 70 years.
• History of antiretroviral or steroid treatment.
• Renal dysfunction.
• Other causes of liver damage.
Interventions Participants were randomly assigned to 2 groups.
Group 1: lamivudine (n = not stated).
Further details: lamivudine: 100 mg/day for 3 months.
Group 2: placebo (n = not stated).
Outcomes None of the outcomes of interest reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor adverse events reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
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Van Hoogstraten 1998
Methods Randomised clinical trial.
Participants Country: Netherlands.
Number randomised: 61.
Post-randomisation dropouts: 2 (3.3%).
Revised sample size: 59.
Mean age: 57 years.
Females: 55 (93.2%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: 0 (0%).
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: non-responders only.
Exclusion criteria
• Decompensated liver disease.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) (n = 32).
Further details: UDCA (low): 10 mg/kg/day for 6 months.
Group 2: UDCA (moderate) (n = 27).
Further details: UDCA (moderate): 20 mg/kg/day for 6 months.
Outcomes Adverse events.
Notes Reasons for post-randomisation dropouts: developed liver failure, lost to follow-up
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Tables with random numbers” (author’s reply).
Allocation concealment (selection bias) Low risk Quote: “Opaque closed envelopes” (author’s reply).
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “randomised open controlled trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “randomised open controlled trial”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
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Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias High risk Quote: “This study was supported in part by ZambonNed-
erland BV, Amersfoort, the Netherlands”
Other bias Low risk Comment: no other source of bias.
Warnes 1987
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 64.
Post-randomisation dropouts: not stated.
Revised sample size: 64.
Mean age: not stated.
Females: not stated.
Symptomatic participants: not stated.
AMA positive: 64 (100%).
Responders: not stated.
Median follow-up period (for all groups): 19 months.
Inclusion criteria
• Symptom status: not stated.
• AMA status: AMA-positive participants only.
• Response status: not stated.
Interventions Participants were randomly assigned to 2 groups.
Group 1: colchicine (n = 34).
Further details: colchicine: 0.5 mg BD; duration: not stated
Group 2: placebo (n = 30).
Outcomes Mortality, adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “To ensure that treatment groups were comparable,
patients were stratified according to serum bilirubin level
at entry (A, < 19/µmol/1; B, 20-34/ µmol/L; C, 35-102/
µmol/L; D, >102/µmol/1). The first patient in any pair was
allocated by the staff pharmacist to the treatment or placebo
group by reference to random tables. The pair was com-
pleted when another patient, in the same bilirubin group
and with an age within 5 years of the first patient, was en-
tered into the study. The second member of the pair was
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allocated to the alternative treatment group. The study was
double-blind”.
Comment: minimisation method used.
Allocation concealment (selection bias) Low risk Quote: “To ensure that treatment groups were comparable,
patients were stratified according to serum bilirubin level
at entry (A, < 19/µmol/1; B, 20-34/ µmol/L; C, 35-102/
µmol/L; D, >102/µmol/1). The first patient in any pair was
allocated by the staff pharmacist to the treatment or placebo
group by reference to random tables. The pair was com-
pleted when another patient, in the same bilirubin group
and with an age within 5 years of the first patient, was en-
tered into the study. The second member of the pair was
allocated to the alternative treatment group. The study was
double-blind”.
Comment: minimisation method used.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
Wiesner 1990
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 40.
Post-randomisation dropouts: 11 (27.5%).
Revised sample size: 29.
Mean age: 46 years.
Females: 28 (96.6%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: not stated.
Median follow-up period (for all groups): 35 months.
Inclusion criteria
148Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wiesner 1990 (Continued)
• Symptom status: not stated.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Cirrhosis or advanced liver disease.
• Renal dysfunction.
• Uncontrolled hypertension.
• Neoplastic disease.
• Skin cancer.
• Previous immunosuppressive therapy.
• Other liver diseases.
Interventions Participants were randomly assigned to 2 groups.
Group 1: ciclosporin (n = 19).
Further details: ciclosporin: 4 mg/kg/day.
Group 2: placebo (n = 10).
Outcomes Mortality, adverse events, liver transplantation.
Notes Reasons for post-randomisation dropouts: follow-up < 1 year.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) Low risk Comment: mortality and morbidity reported.
For-profit bias High risk Quote: “Supported by a grant fromSandoz andby theMayo
foundation”
Other bias Low risk Comment: no other source of bias.
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Wolfhagen 1998
Methods Randomised clinical trial.
Participants Country: Netherlands.
Number randomised: 50.
Post-randomisation dropouts: not stated.
Revised sample size: 50.
Mean age: 52 years.
Females: 45 (90%).
Symptomatic participants: not stated.
AMA positive: not stated.
Responders: 0 (0%).
Mean follow-up period (for all groups): all participants followed up for 12 months
Inclusion criteria
• Symptom status: not stated.
• AMA status: not stated.
• Response status: non-responders only.
Exclusion criteria
• Advanced or decompensated liver disease.
• Alcohol abuse.
• Other causes of liver disease.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (moderate) + azathioprine + glucocorticosteroids (n = 26)
Further details: UDCA: 10 mg/kg/day for 6 months + azathioprine: 50 mg/day for 6
months + prednisolone: 10 mg/day for 6 months
Group 2: UDCA (moderate) (n = 24).
Further details: UDCA: 10 mg/kg/day for 6 months.
Outcomes Adverse events, cirrhosis.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Tables with random numbers” (author’s reply).
Allocation concealment (selection bias) Low risk Quote: “Opaque closed envelopes” (author’s reply).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: identical placebo used in this double-blind trial.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias High risk Quote: “Supported by…Zambon Nederland B.v. and
Glaxo Wellcome Research and Development Ltd”
Other bias Low risk Comment: no other source of bias.
Yokomori 2001
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 11.
Post-randomisation dropouts: not stated.
Revised sample size: 11.
Mean age: 54 years.
Females: 9 (81.8%).
Symptomatic participants: 11 (100%).
AMA positive: not stated.
Responders: not stated.
Mean follow-up period (for all groups): not stated.
Inclusion criteria
• Symptom status: symptomatic participants only.
• AMA status: not stated.
• Response status: not stated.
Exclusion criteria
• Advanced or decompensated liver disease.
• Pregnancy.
• Treatment with immunosuppressants or other drugs that interfere with bile
secretion.
• Severe complications other than primary biliary cholangitis.
Interventions Participants were randomly assigned to 2 groups.
Group 1: UDCA (low) + colestilan (n = 5).
Further details: UDCA: 600 mg/day for 8 weeks + colestilan: 6.42 mg/day for 4 weeks
Group 2: UDCA (low) (n = 6).
Further details: UDCA: 600 mg/day for 8 weeks.
Outcomes Adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Yokomori 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: mortality not reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other source of bias.
AMA: antimitochondrial antibody; BD: twice daily; IV: intravenous;OD: once daily; SAMe: S-adenosylmethionine; SC: subcutaneous;
TUDCA: taurodeoxycholic acid; UDCA: ursodeoxycholic acid.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Angulo 1999b Long-term follow-up of participants included in an included trial (Lindor 1994), but the randomisation was
not maintained.
Angulo 1999c Long-term follow-up of participants included in an included trial (Lindor 1994), but the randomisation was
not maintained.
Angulo 2002 Comparison of different administration schedules of the same dose of UDCA
Attili 1994 Not in people with primary biliary cholangitis.
Avezov 2004a Not a randomised clinical trial.
Avezov 2004b Not a randomised clinical trial.
Bach 2003 Not a randomised clinical trial.
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(Continued)
Batta 1989 Not a randomised clinical trial.
Beukers 1988 Not a randomised clinical trial.
Blanche 1994 Not a randomised clinical trial.
Bonis 2006 Not a randomised clinical trial.
Borum 1990 Not a primary study (editorial).
Bray 1991 Cross-over RCT; no results presented before cross-over.
Carbone 2016 Long-term follow-up of Nevens 2016, but excluded because randomisation not maintained.
Chazouilleres 1995 Not a randomised clinical trial.
Christensen 1986 Not a primary study (letter to editor).
Combes 1989 Not a primary study (editorial).
Combes 2004 Not a primary study (editorial).
Combes 2005b Long-term follow-up of participants in an included RCT (Combes 1995a); however, all participants received
the intervention after the end of the initial study
Copaci 2001 Not a randomised clinical trial.
Corpechot 2000 Long-term follow-up of an included trial (Poupon 1991a); however, all participants received the active inter-
vention at the end of the trial period
Corpechot 2001 Not a primary study (editorial).
Crosignani 1996a Cross-over RCT; no outcomes of interest reported before cross-over
Crosignani 1996b In this RCT of different doses of TUDCA, participants who were intolerant to the drug were replaced. This
affected the randomisation
De la Mora 1994 No separate data on people who were randomised (included non-randomised participants in the results)
Degott 1999 Long-term follow-up of an included trial (Poupon 1991a); however, all participants received the active inter-
vention at the end of the trial period
Dickson 1991 No separate data on people who were randomised (included non-randomised participants in the results)
Emond 1996 Long-term follow-up of an included trial (Combes 1995a); however, all participants received the active inter-
vention at the end of the trial period
Fischer 1967 Not a randomised clinical trial.
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(Continued)
Golovanova 2010 Not a randomised clinical trial.
Heathcote 1993 Not a randomised clinical trial.
Heathcote 1995 Not a primary study.
Hirschfield 2011 Not a randomised clinical trial.
Hishon 1982 Not a randomised clinical trial.
Howat 1966 Not a randomised clinical trial.
Hwang 1993 Cross-over RCT; none of the outcomes of interest reported prior to cross-over
Invernizzi 1996 Cross-over RCT, no results presented before cross-over.
Invernizzi 2015 Not a primary study.
Itakura 2004 Not a primary study.
Jazrawi 1999 Not a randomised clinical trial.
Jones 2006 Not a primary study (letter to editor).
Jorgensen 2002 Long-term follow-up of an included trial (Lindor 1994); however, all participants received the active intervention
at the end of the trial period
Joshi 2002 Not a primary study.
Kaplan 1993 Not a primary study (editorial).
Kaplan 1998 Not a primary study (letter to editor).
Kaplan 2004 Long-term follow-up of an included trial (Kaplan 1999), but the treatment was changed at the completion of
the RCT
Kaplan 2009 Not a primary study (letter to editor).
Kisand 1996 Quasi-randomised study (allocation by case numbers).
Kisand 1998 Quasi-randomised study (allocation by case numbers).
Kowdley 2014a Not a randomised clinical trial.
Kowdley 2014b Not a randomised clinical trial.
Kowdley 2015 Long-term follow-up of Kowdley 2011, but excluded because randomisation was not maintained.
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(Continued)
Kugler 1991 Not a primary study (commentary).
Kurihara 2002 Not a randomised clinical trial.
Lampe 1972 Not a randomised clinical trial.
Larghi 1997 Cross-over RCT; no results presented before cross-over.
Lee 2003 Not a randomised clinical trial.
Leung 2010 Long-term follow-up of a subgroup of participants in an included trial (Kaplan 1999), where additional
interventions were added after completion of the trial period
Leung 2011 Long-term follow-up of a subgroup of participants in an included trial (Kaplan 1999), where additional
interventions were added after completion of the trial period
Leuschner 1990 Not a primary study (review).
Leuschner 1993a Not a primary study (review).
Leuschner 1993b Quasi-randomised study (allocation by alternation).
Leuschner 1996a Quasi-randomised study (allocation by alternation).
Leuschner 1996b Quasi-randomised study (allocation by alternation).
Leuschner 1997 Not a primary study (review).
Leuschner 1998 Not a primary study (review).
Levy 2004 Not a primary study (editorial).
Licinio 2015 Not a primary study (letter to editor).
Lim 2000 Not a randomised clinical trial.
Lindor 1994a Not a randomised clinical trial
Lindor 1995a Long-term follow-up an included RCT (Lindor 1994); however, all participants received the intervention after
the completion of the RCT
Lindor 1995b Not a randomised clinical trial.
Lindor 1995c Not a primary study (review).
Lindor 1996 Long-term follow-up an included RCT (Lindor 1994); however, all participants received the intervention after
the completion of the RCT
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(Continued)
Lindor 2000 Not a primary study (letter to editor).
Lindor 2005 Not a primary study (review).
Lindor 2007 Not a primary study (review).
Lytvyak 2015 Cross-over RCT; no outcomes reported prior to cross-over.
Lytvyak 2016 Not a randomised clinical trial
Miettinen 1993 Quasi-randomised study (allocation by case numbers).
Miettinen 1995 Quasi-randomised study (allocation by case numbers).
Muntoni 2010 Only 4 participants in this trial had primary biliary cholangitis and separate data not available for these 4
participants
Nikolaidis 2006 Only 5 participants had primary biliary cholangitis and only 1 of them received placebo. Separate data not
available on these participants
Ohmoto 2001 Not a randomised clinical trial.
Ohmoto 2006 Not a randomised clinical trial.
Pan 2013 Only 5 participants had primary biliary cholangitis. Separate data not available for these participants
Pares 2009 Not a randomised clinical trial.
Podda 1989 Cross-over study of different doses of UDCA; outcomes not reported at the end of first treatment
Poupon 1989 Not a primary study (review).
Poupon 1990 Not a primary study (review).
Poupon 1991b Not a primary study (commentary).
Poupon 1994 Long-term follow-up of an included trial (Poupon 1991a); however, all participants received the active inter-
vention at the end of the trial period
Poupon 1997 Not a primary study.
Poupon 1999 Not a randomised clinical trial.
Poupon 2003 Not a primary study.
Raedsch 1989 Not a randomised clinical trial.
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Reed 1982 Not a primary study (editorial).
Robson 1994 Not a randomised clinical trial.
Roda 2002 Not a randomised clinical trial.
Savolainen 1983 Unclear whether this was a randomised clinical trial.
Schaffner 1982 Comparison of 2 doses of D-penicillamine with no other treatment as comparator
Setchell 1994 In this RCT of different doses of TUDCA, participants who were intolerant to the drug were replaced. This
affected the randomisation
Setchell 1996 In this RCT of different doses of TUDCA, participants who were intolerant to the drug were replaced. This
affected the randomisation
Stellaard 1979 Not a randomised clinical trial.
Taal 1985 Not a randomised clinical trial.
Tang 2008 Not a pharmacological agent.
Tong 2012 Not a pharmacological agent.
Verma 1999 Cross-over RCT; no results presented before cross-over.
Verma 2000 Not a primary study (review).
Vogel 1988 Not a randomised clinical trial.
Vuoristo 1995 Quasi-randomised study (allocation by case numbers).
Vuoristo 1997 Quasi-randomised study (allocation by case numbers).
Wiesner 1994 Not a randomised clinical trial.
Wolfhagen 1995 Not a randomised clinical trial.
Yan 2007 Not a primary study (letter to editor).
Yano 2002 Not a randomised clinical trial.
Zuin 1991 Symptomatic treatment of dyslipidaemia associated with primary biliary cholangitis
TUDCA: taurodeoxycholic acid; UDCA: ursodeoxycholic acid.
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Characteristics of studies awaiting assessment [ordered by study ID]
O’Brian 1990
Methods Full text not available.
Participants
Interventions
Outcomes
Notes
Zaman 2006
Methods Full text not available.
Participants
Interventions
Outcomes
Notes
Characteristics of ongoing studies [ordered by study ID]
ChiCTR-IPR-16008935
Trial name or title Biochemical Response of PBC-AIH Overlap Syndrome Induced by Ursodeoxycholic Acid Only or Combi-
nation Therapy of Immunosuppressive Agents
Methods Randomised parallel clinical trial
Participants People with primary biliary cholangitis and autoimmune hepatitis overlap syndrome
Interventions Group 1: UDCA + immunosuppression
Further details: not provided.
Group 2: UDCA.
Further details: not provided.
Outcomes Adverse events
Starting date Not stated.
Contact information yangli hx@scu.edu.cn
Notes Status: recruiting.
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EUCTR2015-002698-39-GB
Trial name or title A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Effects of Two
Doses of MBX-8025 in Subjects with Primary Biliary Cirrhosis (PBC) and an Inadequate Response to
Ursodeoxycholic Acid (UDCA)
Methods Randomised, placebo-controlled, double-blind clinical trial.
Participants People with primary biliary cholangitis (non-responders).
Interventions Group 1: MBX-8025.
Further details: not provided.
Group 2: placebo.
Outcomes None of the outcomes of interest for this review measured in this trial
Starting date Not stated.
Contact information KRosemark@cymabay.com
Notes Status: recruiting.
NCT02308111
Trial name or title A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of
Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cirrhosis
Methods Phase 3, double-blind, randomised, placebo-controlled, multicentre study
Participants People with primary biliary cholangitis.
Interventions Group 1: obeticholic acid.
Further details: obeticholic acid 5 mg to 10 mg tablets once daily for the duration of the study based on
tolerability at 3 months
Group 2: placebo.
Further details: 1 tablet daily for the remainder of the study
Outcomes Mortality, liver transplantation, liver decompensation, hepatocellular carcinoma
Starting date December 2014.
Contact information dshapiro@interceptpharma.com
Notes Status: recruiting.
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NCT02701166
Trial name or title The Effect of Bezafibrate on Cholestatic Itch
Methods Double-blind, randomised, placebo-controlled clinical trial.
Participants People with primary biliary cholangitis.
Interventions Group 1: bezafibrate.
Further details: bezafibrate 400 mg/day.
Group 2: placebo.
Outcomes None of the outcomes of interest for this review are measured in this trial
Starting date February 2016.
Contact information u.h.beuers@amc.uva.nl
Notes Status: recruiting.
NCT02823353
Trial name or title Fenofibrate in Combination with Ursodeoxycholic Acid in Primary Biliary Cirrhosis: a Randomized Control
Study
Methods Phase 3, open-label, randomised clinical trial.
Participants People with primary biliary cholangitis.
Interventions Group 1: UDCA + fenofibrate.
Further details: not provided.
Group 2: UDCA.
Further details: not provided.
Outcomes None of the outcomes of interest for this review are measured in this trial
Starting date January 2016.
Contact information hanying@fmmu.edu.cn
Notes Status: recruiting.
NCT02823366
Trial name or title Fenofibrate for Patients with Primary Biliary Cirrhosis who had an Inadequate Response to Ursodeoxycholic
Acid
Methods Phase 3, open-label, randomised clinical trial.
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NCT02823366 (Continued)
Participants People with primary biliary cholangitis.
Interventions Group 1: UDCA + fenofibrate
Further details: not provided.
Group 2: UDCA.
Further details: not provided.
Outcomes None of the outcomes of interest for this review measured in this trial
Starting date January 2016.
Contact information hanying@fmmu.edu.cn
Notes Status: recruiting.
May be the same as NCT02823353.
NCT02937012
Trial name or title Efficacy and Security of Bezafibrate in Patients with Primary Biliary Cirrhosis without Biochemical Response
to Ursodeoxycholic Acid: a Randomized, Double-blind, Placebo-controlled Trial
Methods Randomised, double-blind, placebo-controlled clinical trial.
Participants People with primary biliary cholangitis (non-responders).
Interventions Group 1: UDCA + bezafibrate.
Further details: bezafibrate 200 mg capsule every 12 hours + UDCA 13 mg/kg/day to 15 mg/kg/day for 12
months
Group 2: UDCA + placebo.
Further details: placebo capsule (for bezafibrate 200 mg capsule) every 12 hours + UDCA 13 mg/kg/day to
15 mg/kg/day for 12 months
Outcomes Quality of life.
Starting date October 2016.
Contact information ericlopezmendez@yahoo.com.mx
sergio sg@hotmail.com
Notes Status: recruiting.
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NCT02943447
Trial name or title A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and
Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis without Cirrhosis
Methods Randomised, double-blind, placebo-controlled clinical trial.
Participants People with primary biliary cholangitis.
Interventions Group 1: GS-9674.
Further details: GS-9674 30 mg for 12 weeks.
Group 2: placebo.
Outcomes Adverse events.
Starting date December 2016.
Contact information GS-US-427-4024@Gilead.com
Notes Status: recruiting.
NCT02965911
Trial name or title A Randomized Controlled Clinical Trial on the Efficacy and Safety of Fenofibrate Combined with Ursodeoxy-
cholic Acid in PBC Patients with an Incomplete Biochemical Response to UDCA
Methods Open-label, randomised clinical trial.
Participants People with primary biliary cholangitis.
Interventions Group 1: fenofibrate + UDCA.
Further details: UDCA 13 mg/kg/day to 15 mg/kg/day + fenofibrate 200 mg once daily for 12 months
Group 2: UDCA.
Further details: UDCA 13 mg/kg/day to 15 mg/kg/day.
Outcomes None of the outcomes of interest for this review measured in this trial
Starting date January 2016.
Contact information zszou302@163.com
Notes Status: recruiting.
UDCA: ursodeoxycholic acid.
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D A T A A N D A N A L Y S E S
Comparison 1. Main analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at maximal follow-up 28 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Azathioprine versus no
intervention
2 224 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.32, 0.98]
1.2 Chlorambucil versus no
intervention
1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 3.28]
1.3 Colchicine versus no
intervention
2 122 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.32, 1.85]
1.4 Cyclosporin versus no
intervention
3 390 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.51, 1.50]
1.5 D-Penicillamine versus no
intervention
5 423 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.57, 1.44]
1.6 Glucocorticosteroids
versus no intervention
1 36 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.14, 2.92]
1.7 Malotilate versus no
intervention
1 101 Odds Ratio (M-H, Fixed, 95% CI) 2.0 [0.47, 8.48]
1.8 Methotrexate versus no
intervention
1 60 Odds Ratio (M-H, Fixed, 95% CI) 8.83 [1.01, 76.96]
1.9 UDCA versus no
intervention
6 734 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.60, 1.64]
1.10 Bezafibrate plus UDCA
versus UDCA
1 27 Odds Ratio (M-H, Fixed, 95% CI) 9.67 [0.45, 207.78]
1.11 Colchicine plus UDCA
versus UDCA
2 158 Odds Ratio (M-H, Fixed, 95% CI) 1.84 [0.38, 8.91]
1.12 Methotrexate plus
UDCA versus UDCA
2 290 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.55, 2.51]
1.13 Obeticholic acid plus
UDCA versus UDCA
1 216 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.06, 38.46]
2 Mortality (< 1 year) 8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Azathioprine versus no
intervention
1 39 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.16, 2.10]
2.2 Colchicine versus no
intervention
1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.22, 3.33]
2.3 Cyclosporin versus no
intervention
1 12 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 3.63]
2.4 D-Penicillamine versus no
intervention
1 189 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.35, 1.42]
2.5 Ursodeoxycholic acid
(UDCA) versus no intervention
1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Colchicine plus UDCA
versus UDCA
1 84 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.13, 7.45]
2.7 Methotrexate plus UDCA
versus UDCA
1 25 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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2.8 Obeticholic acid plus
UDCA versus UDCA
1 216 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.06, 38.46]
3 Mortality (1 to 5 years) 20 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Azathioprine versus no
intervention
1 185 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.30, 1.04]
3.2 Chlorambucil versus no
intervention
1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 3.28]
3.3 Colchicine versus no
intervention
1 58 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.22, 2.25]
3.4 Cyclosporin versus no
intervention
2 378 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.54, 1.64]
3.5 D-Penicillamine versus no
intervention
4 234 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.59, 2.08]
3.6 Glucocorticosteroids
versus no intervention
1 36 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.14, 2.92]
3.7 Malotilate versus no
intervention
1 101 Odds Ratio (M-H, Fixed, 95% CI) 2.0 [0.47, 8.48]
3.8 Methotrexate versus no
intervention
1 60 Odds Ratio (M-H, Fixed, 95% CI) 8.83 [1.01, 76.96]
3.9 UDCA versus no
intervention
5 716 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.60, 1.64]
3.10 Bezafibrate plus UDCA
versus UDCA
1 27 Odds Ratio (M-H, Fixed, 95% CI) 9.67 [0.45, 207.78]
3.11 Colchicine plus UDCA
versus UDCA
1 74 Odds Ratio (M-H, Fixed, 95% CI) 5.28 [0.24, 113.87]
3.12 Methotrexate plus
UDCA versus UDCA
1 265 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.55, 2.51]
4 Serious adverse events
(proportion)
11 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Colchicine versus no
intervention
1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 D-Penicillamine versus no
intervention
1 52 Odds Ratio (M-H, Fixed, 95% CI) 28.77 [1.57, 526.67]
4.3 Obeticholic acid versus no
intervention
1 165 Odds Ratio (M-H, Fixed, 95% CI) 1.83 [0.21, 15.73]
4.4 UDCA versus no
intervention
3 380 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 UDCA versus bezafibrate 1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Bezafibrate plus UDCA
versus UDCA
1 22 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Colchicine plus UDCA
versus UDCA
1 74 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 78.14]
4.8 Lamivudine plus
zidovudine plus UDCA versus
UDCA
1 59 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.04, 5.43]
4.9 Obeticholic acid plus
UDCA versus UDCA
1 216 Odds Ratio (M-H, Fixed, 95% CI) 3.58 [1.02, 12.51]
5 Serious adverse events (number
of events)
1 Rate Ratio (Fixed, 95% CI) Subtotals only
5.1 Obeticholic acid plus
UDCA versus UDCA
1 216 Rate Ratio (Fixed, 95% CI) 1.66 [0.75, 3.66]
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6 Adverse events (proportion) 19 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Cyclosporin versus no
intervention
3 390 Odds Ratio (M-H, Fixed, 95% CI) 3.04 [1.98, 4.68]
6.2 D-Penicillamine versus no
intervention
2 287 Odds Ratio (M-H, Fixed, 95% CI) 4.51 [2.56, 7.93]
6.3 Malotilate versus no
intervention
1 101 Odds Ratio (M-H, Fixed, 95% CI) 11.43 [1.40, 93.04]
6.4 Obeticholic acid versus no
intervention
1 165 Odds Ratio (M-H, Fixed, 95% CI) 4.58 [1.31, 15.95]
6.5 UDCA versus no
intervention
3 380 Odds Ratio (M-H, Fixed, 95% CI) 1.45 [0.50, 4.25]
6.6 Azathioprine plus UDCA
versus UDCA
1 42 Odds Ratio (M-H, Fixed, 95% CI) 19.67 [0.94, 413.50]
6.7 Bezafibrate versus UDCA 1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.8 Bezafibrate plus UDCA
versus UDCA
1 22 Odds Ratio (M-H, Fixed, 95% CI) 3.29 [0.12, 89.81]
6.9 Colchicine plus UDCA
versus UDCA
2 42 Odds Ratio (M-H, Fixed, 95% CI) 6.20 [0.63, 60.80]
6.10 Colestilan plus UDCA
versus UDCA
1 11 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.11 Glucocorticosteroids
plus UDCA versus UDCA
2 135 Odds Ratio (M-H, Fixed, 95% CI) 5.54 [1.35, 22.84]
6.12 Methotrexate plus
UDCA versus UDCA
1 25 Odds Ratio (M-H, Fixed, 95% CI) 115.0 [4.98, 2657.
48]
6.13 TauroUDCA versus
UDCA
1 30 Odds Ratio (M-H, Fixed, 95% CI) 21.0 [2.16, 204.61]
6.14 Glucocorticosteroids
plus UDCA versus azathioprine
plus UDCA
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.08, 2.12]
7 Adverse events (number) 14 Rate Ratio (Random, 95% CI) Subtotals only
7.1 Chlorambucil versus no
intervention
1 24 Rate Ratio (Random, 95% CI) 3.67 [1.04, 12.87]
7.2 Cyclosporin versus no
intervention
3 390 Rate Ratio (Random, 95% CI) 2.58 [1.26, 5.31]
7.3 D-Penicillamine versus no
intervention
3 303 Rate Ratio (Random, 95% CI) 2.99 [1.04, 8.63]
7.4 Malotilate versus no
intervention
1 101 Rate Ratio (Random, 95% CI) 6.13 [1.38, 27.14]
7.5 Obeticholic acid versus no
intervention
1 76 Rate Ratio (Random, 95% CI) 1.41 [1.13, 1.75]
7.6 Azathioprine plus
glucocorticosteroids plus
UDCA versus UDCA
1 50 Rate Ratio (Random, 95% CI) 1.32 [0.88, 1.97]
7.7 Bezafibrate plus UDCA
versus UDCA
1 29 Rate Ratio (Random, 95% CI) 11.79 [0.65, 213.14]
7.8 Colchicine plus UDCA
versus UDCA
1 24 Rate Ratio (Random, 95% CI) 5.91 [0.28, 123.08]
7.9 Methotrexate plus UDCA
versus UDCA
1 27 Rate Ratio (Random, 95% CI) 30.64 [1.84, 510.76]
7.10 TauroUDCA versus
UDCA
1 191 Rate Ratio (Random, 95% CI) 1.17 [0.81, 1.71]
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8 Liver transplantation 11 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Cyclosporin versus no
intervention
2 378 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.43, 1.72]
8.2 D-Penicillamine versus no
intervention
1 189 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.06, 15.05]
8.3 Methotrexate versus no
intervention
1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.58]
8.4 UDCA versus no
intervention
5 640 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.48, 1.68]
8.5 Bezafibrate plus UDCA
versus UDCA
1 27 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.6 Methotrexate plus UDCA
versus UDCA
1 265 Odds Ratio (M-H, Fixed, 95% CI) 0.70 [0.35, 1.39]
9 Decompensated liver disease 7 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 D-Penicillamine versus no
active treatment
1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 UDCA versus no
intervention
2 237 Odds Ratio (M-H, Fixed, 95% CI) 1.60 [0.86, 2.98]
9.3 Azathioprine plus UDCA
versus UDCA
1 42 Odds Ratio (M-H, Fixed, 95% CI) 0.52 [0.05, 5.18]
9.4 Colchicine plus UDCA
versus UDCA
1 84 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.04, 1.07]
9.5 Glucocorticosteroids plus
UDCA versus UDCA
1 66 Odds Ratio (M-H, Fixed, 95% CI) 0.55 [0.11, 2.69]
9.6 Methotrexate plus UDCA
versus UDCA
1 265 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.77, 2.33]
9.7 Obeticholic acid plus
UDCA versus UDCA
1 216 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.06, 38.46]
9.8 Glucocorticosteroids plus
UDCA versus azathioprine
plus UDCA
1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.10, 11.18]
10 Cirrhosis 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Azathioprine versus no
intervention
1 31 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.18, 3.41]
10.2 UDCA versus no
intervention
1 22 Odds Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 1.53]
10.3 Azathioprine plus
glucocorticosteroids plus
UDCA versus UDCA
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.03, 2.90]
Comparison 2. Stratified by dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at maximal follow-up 29 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Azathioprine versus no
intervention
2 224 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.32, 0.98]
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1.2 Chlorambucil versus no
intervention
1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 3.28]
1.3 Colchicine versus no
intervention
2 122 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.32, 1.85]
1.4 Cyclosporin versus no
intervention
3 390 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.51, 1.50]
1.5 D-Penicillamine versus no
intervention
5 423 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.57, 1.44]
1.6 Glucocorticosteroids
versus no intervention
1 36 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.14, 2.92]
1.7 Malotilate versus no
intervention
1 101 Odds Ratio (M-H, Fixed, 95% CI) 2.0 [0.47, 8.48]
1.8 Methotrexate versus no
intervention
1 60 Odds Ratio (M-H, Fixed, 95% CI) 8.83 [1.01, 76.96]
1.9 UDCA (low) versus no
intervention
2 64 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.47]
1.10 UDCA (moderate)
versus no intervention
4 670 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.62, 1.77]
1.11 UDCA (low) versus
UDCA (high)
1 106 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.06, 17.06]
1.12 UDCA (moderate)
versus UDCA (high)
1 103 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 9.05]
1.13 UDCA (low) plus
colchicine versus UDCA (low)
1 84 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.13, 7.45]
1.14 UDCA (low) plus
methotrexate versus UDCA
(low)
1 25 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.15 UDCA (moderate)
versus UDCA (low)
1 101 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.72]
1.16 Bezafibrate plus UDCA
(moderate) versus UDCA
(moderate)
1 27 Odds Ratio (M-H, Fixed, 95% CI) 9.67 [0.45, 207.78]
1.17 Colchicine plus UDCA
(moderate) versus UDCA
(moderate)
1 74 Odds Ratio (M-H, Fixed, 95% CI) 5.28 [0.24, 113.87]
1.18 Methotrexate plus
UDCA (moderate) versus
UDCA (moderate)
1 265 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.55, 2.51]
1.19 Obeticholic acid (low)
plus UDCA (moderate) versus
UDCA (moderate)
1 216 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.06, 38.46]
2 Mortality (< 1 year) 9 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Azathioprine versus no
intervention
1 39 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.16, 2.10]
2.2 Colchicine versus no
intervention
1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.22, 3.33]
2.3 Cyclosporin versus no
intervention
1 12 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 3.63]
2.4 D-Penicillamine versus no
intervention
1 189 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.35, 1.42]
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2.5 UDCA (low) versus no
intervention
1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 UDCA (low) versus
UDCA (high)
1 106 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.06, 17.06]
2.7 UDCA (moderate) versus
UDCA (high)
1 103 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 9.05]
2.8 Obeticholic acid (low)
plus UDCA (moderate) versus
UDCA (moderate)
1 216 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.06, 38.46]
2.9 UDCA (low) plus
colchicine versus UDCA (low)
1 84 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.13, 7.45]
2.10 UDCA (low) plus
methotrexate versus UDCA
(low)
1 25 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.11 UDCA (moderate)
versus UDCA (low)
1 101 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.72]
3 Mortality (1 to 5 years) 20 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Azathioprine versus no
intervention
1 185 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.30, 1.04]
3.2 Chlorambucil versus no
intervention
1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 3.28]
3.3 Colchicine versus no
intervention
1 58 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.22, 2.25]
3.4 Cyclosporin versus no
intervention
2 378 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.54, 1.64]
3.5 D-Penicillamine versus no
intervention
4 234 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.59, 2.08]
3.6 Glucocorticosteroids
versus no intervention
1 36 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.14, 2.92]
3.7 Malotilate versus no
intervention
1 101 Odds Ratio (M-H, Fixed, 95% CI) 2.0 [0.47, 8.48]
3.8 Methotrexate versus no
intervention
1 60 Odds Ratio (M-H, Fixed, 95% CI) 8.83 [1.01, 76.96]
3.9 UDCA (low) versus no
intervention
1 46 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.47]
3.10 UDCA (moderate)
versus no intervention
4 670 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.62, 1.77]
3.11 Bezafibrate plus UDCA
(moderate) versus UDCA
(moderate)
1 27 Odds Ratio (M-H, Fixed, 95% CI) 9.67 [0.45, 207.78]
3.12 Colchicine plus UDCA
(moderate) versus UDCA
(moderate)
1 74 Odds Ratio (M-H, Fixed, 95% CI) 5.28 [0.24, 113.87]
3.13 Methotrexate plus
UDCA (moderate) versus
UDCA (moderate)
1 265 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.55, 2.51]
4 Serious adverse events
(proportion)
12 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Colchicine versus no
intervention
1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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4.2 D-Penicillamine versus no
intervention
1 52 Odds Ratio (M-H, Fixed, 95% CI) 28.77 [1.57, 526.67]
4.3 Obeticholic acid (high)
versus no intervention
1 79 Odds Ratio (M-H, Fixed, 95% CI) 5.14 [0.57, 46.17]
4.4 Obeticholic acid (low)
versus no intervention
1 76 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.22]
4.5 Obeticholic acid
(moderate) versus no
intervention
1 86 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.05, 13.01]
4.6 UDCA (low) versus no
intervention
1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 UDCA (moderate) versus
no intervention
2 362 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 UDCA (low) versus
bezafibrate
1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 Obeticholic acid (low)
versus obeticholic acid (high)
1 79 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.00, 1.61]
4.10 Obeticholic acid
(moderate) versus obeticholic
acid (high)
1 89 Odds Ratio (M-H, Fixed, 95% CI) 0.15 [0.02, 1.37]
4.11 Obeticholic acid
(moderate) versus obeticholic
acid (low)
1 86 Odds Ratio (M-H, Fixed, 95% CI) 2.43 [0.10, 61.39]
4.12 Lamivudine plus
zidovudine plus UDCA
(moderate) versus UDCA
(moderate)
1 59 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.04, 5.43]
4.13 UDCA (moderate)
versus obeticholic acid (low)
plus UDCA (moderate)
1 216 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.08, 0.98]
4.14 Bezafibrate plus UDCA
(low) versus UDCA (low)
1 22 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.15 UDCA (moderate)
versus UDCA (low)
1 59 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.16 Colchicine plus UDCA
(moderate) versus UDCA
(moderate)
1 74 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 78.14]
5 Serious adverse events (number
of events)
1 Rate Ratio (Fixed, 95% CI) Subtotals only
5.1 Obeticholic acid (low)
plus UDCA (moderate) versus
UDCA (moderate)
1 Rate Ratio (Fixed, 95% CI) 1.66 [0.75, 3.66]
6 Adverse events (proportion) 20 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Cyclosporin versus no
intervention
3 390 Odds Ratio (M-H, Fixed, 95% CI) 3.04 [1.98, 4.68]
6.2 D-Penicillamine versus no
intervention
2 287 Odds Ratio (M-H, Fixed, 95% CI) 4.51 [2.56, 7.93]
6.3 Malotilate versus no
intervention
1 101 Odds Ratio (M-H, Fixed, 95% CI) 11.43 [1.40, 93.04]
6.4 Obeticholic acid (high)
versus no intervention
1 79 Odds Ratio (M-H, Fixed, 95% CI) 16.6 [0.90, 305.59]
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6.5 Obeticholic acid (low)
versus no intervention
1 76 Odds Ratio (M-H, Fixed, 95% CI) 1.59 [0.41, 6.17]
6.6 Obeticholic acid
(moderate) versus no
intervention
1 86 Odds Ratio (M-H, Fixed, 95% CI) 8.81 [1.01, 76.73]
6.7 UDCA (low) versus no
intervention
1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.8 UDCA (moderate) versus
no intervention
2 362 Odds Ratio (M-H, Fixed, 95% CI) 1.45 [0.50, 4.25]
6.9 Glucocorticosteroids plus
UDCA (moderate) versus
azathioprine plus UDCA
(moderate)
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.08, 2.12]
6.10 UDCA (low) versus
bezafibrate
1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.11 Obeticholic acid (low)
versus obeticholic acid (high)
1 79 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.00, 1.78]
6.12 Obeticholic acid
(moderate) versus obeticholic
acid (high)
1 89 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.02, 9.62]
6.13 Obeticholic acid
(moderate) versus obeticholic
acid (low)
1 86 Odds Ratio (M-H, Fixed, 95% CI) 5.53 [0.59, 51.70]
6.14 Bezafibrate plus UDCA
(low) versus UDCA (low)
1 22 Odds Ratio (M-H, Fixed, 95% CI) 3.29 [0.12, 89.81]
6.15 Colestilan plus UDCA
(low) versus UDCA (low)
1 11 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.16 Methotrexate plus
UDCA (low) versus UDCA
(low)
1 25 Odds Ratio (M-H, Fixed, 95% CI) 115.0 [4.98, 2657.
48]
6.17 UDCA (moderate)
versus UDCA (low)
1 59 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.18 Azathioprine plus
UDCA (moderate) versus
UDCA (moderate)
1 42 Odds Ratio (M-H, Fixed, 95% CI) 19.67 [0.94, 413.50]
6.19 Colchicine plus UDCA
(moderate) versus UDCA
(moderate)
2 42 Odds Ratio (M-H, Fixed, 95% CI) 6.20 [0.63, 60.80]
6.20 Glucocorticosteroids
plus UDCA (moderate) versus
UDCA (moderate)
2 135 Odds Ratio (M-H, Fixed, 95% CI) 5.54 [1.35, 22.84]
6.21 TauroUDCA (moderate)
versus UDCA (moderate)
1 30 Odds Ratio (M-H, Fixed, 95% CI) 21.0 [2.16, 204.61]
7 Adverse events (number) 15 Rate Ratio (Fixed, 95% CI) Subtotals only
7.1 Chlorambucil versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 3.67 [1.04, 12.87]
7.2 Cyclosporin versus no
intervention
3 Rate Ratio (Fixed, 95% CI) 1.87 [1.51, 2.32]
7.3 D-Penicillamine versus no
intervention
3 Rate Ratio (Fixed, 95% CI) 2.64 [1.78, 3.91]
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7.4 Malotilate versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 6.13 [1.38, 27.14]
7.5 Obeticholic acid (high)
versus no intervention
1 Rate Ratio (Fixed, 95% CI) 1.91 [1.50, 2.44]
7.6 Obeticholic acid (low)
versus no intervention
1 Rate Ratio (Fixed, 95% CI) 1.05 [0.80, 1.39]
7.7 Obeticholic acid
(moderate) versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 1.25 [0.97, 1.62]
7.8 Obeticholic acid (low)
versus obeticholic acid (high)
1 Rate Ratio (Fixed, 95% CI) 0.55 [0.43, 0.70]
7.9 Obeticholic acid
(moderate) versus obeticholic
acid (high)
1 Rate Ratio (Fixed, 95% CI) 0.66 [0.53, 0.81]
7.10 Obeticholic acid
(moderate) versus obeticholic
acid (low)
1 Rate Ratio (Fixed, 95% CI) 1.19 [0.93, 1.53]
7.11 UDCA (low) versus
UDCA (high)
1 Rate Ratio (Fixed, 95% CI) 2.08 [0.78, 5.53]
7.12 UDCA (moderate)
versus UDCA (high)
1 Rate Ratio (Fixed, 95% CI) 0.73 [0.21, 2.60]
7.13 UDCA (low) plus
methotrexate versus UDCA
(low)
1 Rate Ratio (Fixed, 95% CI) 30.64 [1.84, 510.76]
7.14 UDCA (moderate)
versus UDCA (low)
1 Rate Ratio (Fixed, 95% CI) 0.35 [0.11, 1.10]
7.15 Azathioprine plus
glucocorticosteroids plus
UDCA (moderate) versus
UDCA (moderate)
1 Rate Ratio (Fixed, 95% CI) 1.32 [0.88, 1.97]
7.16 Bezafibrate plus UDCA
(moderate) versus UDCA
(moderate)
1 Rate Ratio (Fixed, 95% CI) 11.79 [0.65, 213.14]
7.17 Colchicine plus UDCA
(moderate) versus UDCA
(moderate)
1 Rate Ratio (Fixed, 95% CI) 5.91 [0.28, 123.08]
7.18 TauroUDCA (moderate)
versus UDCA (moderate)
1 Rate Ratio (Fixed, 95% CI) 1.17 [0.81, 1.71]
8 Liver transplantation 12 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Cyclosporin versus no
intervention
2 378 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.43, 1.72]
8.2 D-Penicillamine versus no
intervention
1 189 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.06, 15.05]
8.3 Methotrexate versus no
intervention
1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.58]
8.4 UDCA (low) versus no
intervention
2 162 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.24, 4.06]
8.5 UDCA (moderate) versus
no intervention
3 478 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.44, 1.76]
8.6 UDCA (low) versus
UDCA (high)
1 106 Odds Ratio (M-H, Fixed, 95% CI) 3.17 [0.13, 79.71]
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8.7 UDCA (moderate) versus
UDCA (high)
1 103 Odds Ratio (M-H, Fixed, 95% CI) 3.37 [0.13, 84.70]
8.8 UDCA (moderate) versus
UDCA (low)
1 101 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.06, 17.47]
8.9 Bezafibrate plus UDCA
(moderate) versus UDCA
(moderate)
1 27 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.10 Methotrexate plus
UDCA (moderate) versus
UDCA (moderate)
1 265 Odds Ratio (M-H, Fixed, 95% CI) 0.70 [0.35, 1.39]
9 Decompensated liver disease 7 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 D-Penicillamine versus no
intervention
1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 UDCA (moderate) versus
no intervention
2 351 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.84, 2.12]
9.3 Obeticholic acid (low)
plus UDCA (moderate) versus
UDCA (moderate)
1 216 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.06, 38.46]
9.4 UDCA (low) plus
colchicine versus UDCA (low)
1 84 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.04, 1.07]
9.5 Azathioprine plus UDCA
(moderate) versus UDCA
(moderate)
1 42 Odds Ratio (M-H, Fixed, 95% CI) 0.52 [0.05, 5.18]
9.6 Glucocorticosteroids plus
UDCA (moderate) versus
UDCA (moderate)
1 66 Odds Ratio (M-H, Fixed, 95% CI) 0.55 [0.11, 2.69]
9.7 Methotrexate plus UDCA
(moderate) versus UDCA
(moderate)
1 151 Odds Ratio (M-H, Fixed, 95% CI) 2.00 [0.79, 5.04]
9.8 Glucocorticosteroids plus
UDCA (moderate) versus
azathioprine plus UDCA
(moderate)
1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.10, 11.18]
10 Cirrhosis 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Azathioprine versus no
intervention
1 31 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.18, 3.41]
10.2 UDCA (low) versus no
intervention
1 22 Odds Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 1.53]
10.3 Azathioprine plus
glucocorticosteroids plus
UDCA (moderate) versus
UDCA (moderate)
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.03, 2.90]
172Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L T A B L E S
Table 1. Characteristics of included studies arranged by comparison
Study name No participants
randomised
Post-randomi-
sation dropouts
No participants
for whom out-
come was re-
ported
Intervention(s) Control Mean follow-up
period
(months)
Smart 1990 20 Not stated 20 Antioxidants No intervention Not stated
Christensen
1985
248 63 185 Azathioprine No intervention 63
Heathcote 1976 45 6 39 Azathioprine No intervention Not stated
Hoofnagle 1986 24 0 24 Chlorambucil No intervention 52
Bodenheimer
1988
57 10 47 Colchicine No intervention 33
Kaplan 1986 60 3 57 Colchicine No intervention 24
Warnes 1987 64 Not stated 64* Colchicine No intervention 19 (median)
Bobadilla 1994 40 Not stated 40 Colchicine +
UDCA
No intervention 12
Lombard 1993 349 0 349 Ciclosporin No intervention 31 (median)
Minuk 1988 12 0 12 Ciclosporin No intervention Not stated
Wiesner 1990 40 11 29 Ciclosporin No intervention 35 (median)
Dickson 1985 309 82 227 D-Penicillamine No intervention 60 (median)
Epstein 1979 98 Not stated 98 D-Penicillamine No intervention 66
Macklon 1982 60 0 60 D-Penicillamine No intervention 37
Matloff 1982 52 0 52 D-Penicillamine No intervention 24
Neuberger 1985 189 Not stated 189 D-Penicillamine No intervention Not stated
Taal 1983 24 Not stated 24 D-Penicillamine No intervention 18
Triger 1980 35 Not stated 35 D-Penicillamine No intervention Not stated
Mitchison 1989 36 0 36 Glucocorticos-
teroids
No intervention 36
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Table 1. Characteristics of included studies arranged by comparison (Continued)
Ueno 2005 20 Not stated 20 Lamivudine No intervention Not stated
Mitchison 1993 104 3 101 Malotilate No intervention 25 (median)
Hendrickse
1999
60 Not stated 60 Methotrexate No intervention 68
Steenbergen
1994
14 Not stated 14 Methotrexate +
UDCA
No intervention 24
Mayo 2015 45 3 42 NGM282 No intervention Not stated
Bowlus 2014 216 Not stated 216 Obeticholic acid No intervention 12
Hirschfield 2015 165 0 165 Obeticholic acid No intervention 3
Kowdley 2014a 59 Not stated 59 Obeticholic acid No intervention Not stated
Manzillo 1993a 32 Not stated 32 S-Adenosyl me-
thionine
No intervention 1
Manzillo 1993b 6 Not stated 6 S-Adenosyl me-
thionine
No intervention 2
Cash 2013 21 8 13 Simvastatin No intervention 12
Askari 2010 28 0 28 Tetrathiomolyb-
date
No intervention Not stated
McCormick
1994
18 0 18 Thalidomide No intervention Not stated
Arora 1990 9 Not stated 9 UDCA No intervention 5
Battezzati 1993 88 2 86 UDCA No intervention 6
Combes 1995a 151 0 151 UDCA No intervention 24
Eriksson 1997 116 15 101 UDCA No intervention 24
Heathcote 1994 222 Not stated 222 UDCA No intervention 24
Leuschner 1989 20 0 18 UDCA No intervention 12
Lim 1994 32 Not stated 32 UDCA No intervention Not stated
Lindor 1994 180 10 170 UDCA No intervention 24
Oka 1990 52 7 45 UDCA No intervention Not stated
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Table 1. Characteristics of included studies arranged by comparison (Continued)
Papatheodoridis
2002
92 6 86 UDCA No intervention 89
Pares 2000 192 0 192 UDCA No intervention 41 (median)
Poupon 1991a 149 3 146 UDCA No intervention Not stated
Senior 1991 20 1 19 UDCA No intervention 18
Turner 1994 46 0 46 UDCA No intervention 24
Goddard 1994 57 Not stated 57 Intervention 1:
UDCA
Intervention 2:
colchicine
Intervention
3: colchicine +
UDCA
No intervention 15
Wolfhagen 1998 50 Not stated 50 Azathioprine
+ glucocorticos-
teroids + UDCA
UDCA 12
Iwasaki 2008a 45 Not stated 45 Bezafibrate UDCA 12
Kurihara 2000 24 Not stated 24 Bezafibrate UDCA Not stated
Hosonuma 2015 27 0 27 Bezafibrate +
UDCA
UDCA 96
Iwasaki 2008b 22 Not stated 22 Bezafibrate +
UDCA
UDCA 12
Kanda 2003 22 0 22 Bezafibrate +
UDCA
UDCA 7
Nakai 2000 23 Not stated 23 Bezafibrate +
UDCA
UDCA 12
Almasio 2000 90 6 84 Colchicine +
UDCA
UDCA Not stated
Ikeda 1996 22 0 22 Colchicine +
UDCA
UDCA 24
Poupon 1996 74 Not stated 74 Colchicine +
UDCA
UDCA 24
Raedsch 1993 28 8 20 Colchicine +
UDCA
UDCA 24
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Table 1. Characteristics of included studies arranged by comparison (Continued)
Yokomori 2001 11 Not stated 11 Colestilan +
UDCA
UDCA Not stated
Liberopoulos
2010
10 Not stated 10 Fenofibrate +
UDCA
UDCA Not stated
Leuschner 1999 40 0 39 Glucocorticos-
teroids + UDCA
UDCA 24
Rautiainen 2005 77 8 69 Glucocorticos-
teroids + UDCA
UDCA 36
Gao 2012 79 Not stated 79 Intervention
1: glucocorticos-
teroids + UDCA
Intervention
2: azathioprine +
UDCA
UDCA Not stated
Mason 2008 59 0 59 Lamivudine + zi-
dovudine +
UDCA
UDCA 6
Combes 2005 265 0 265 Methotrexate +
UDCA
UDCA 91 (median)
Gonzalezkoch
1997
25 Not stated 25 Methotrexate +
UDCA
UDCA 11
Nevens 2016 217 Not stated 216 Obeticholic acid
+ UDCA
UDCA 12
Ferri 1993 30 0 30 TUDCA UDCA 6
Ma 2016 199 8 191 TUDCA UDCA 6
Kaplan 1999 87 2 85 Colchicine Methotrexate 24
Comparison of doses Comparison of doses
Lindor 1997 150 Not stated 150 Intervention 1:
UDCA (high)
Intervention 2:
UDCA (moder-
ate)
UDCA (low) 12
Angulo 1999a 155 Not stated 155 Intervention 1:
UDCA (high)
Intervention 2:
UDCA (low) 12
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Table 1. Characteristics of included studies arranged by comparison (Continued)
UDCA (moder-
ate)
VanHoogstraten
1998
61 2 59 UDCA (moder-
ate)
UDCA (low) Not stated
Mazzarella 2002 42 Not stated 42 UDCA (high) UDCA (moder-
ate)
72
TUDCA: taurodeoxycholic acid; UDCA: ursodeoxycholic acid.
Table 2. Risk of bias arranged according to comparisons
Name of
studies
Interven-
tion(s)
Control Random
sequence
genera-
tion
Alloca-
tion con-
cealment
Blinding
of partic-
ipants
and
health
profes-
sionals
Blinding
of out-
come as-
sessors
Missing
outcome
bias
Selec-
tive out-
come re-
porting
For-
profit
bias
Other
bias
Smart
1990
Antioxi-
dants
No inter-
vention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Chris-
tensen
1985
Azathio-
prine
No inter-
vention
Unclear Unclear Low Low High High High Low
Heath-
cote
1976
Azathio-
prine
No inter-
vention
Unclear Unclear High High High High Low Low
Hoofna-
gle
1986
Chloram-
bucil
No inter-
vention
Low Low High High Low Low Low Low
Boden-
heimer
1988
Colchicine
No inter-
vention
Unclear Unclear Low Low High High High Low
Kaplan
1986 Colchicine
No inter-
vention
Unclear Unclear Unclear Unclear High High Unclear Low
Warnes
1987 Colchicine
No inter-
vention
Low Low Low Low Unclear Low Unclear Low
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Table 2. Risk of bias arranged according to comparisons (Continued)
Bobadilla
1994 Colchicine
+ UDCA
No inter-
vention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Lombard
1993
Ci-
closporin
No inter-
vention
Unclear Unclear Low Low Low Low High Low
Minuk
1988
Ci-
closporin
No inter-
vention
Unclear Unclear Low Unclear Unclear Low High Low
Wiesner
1990
Ci-
closporin
No inter-
vention
Unclear Unclear Low Low Unclear Low High Low
Dickson
1985
D-Peni-
cillamine
No inter-
vention
Low Low Low Low High High High High
Epstein
1979
D-Peni-
cillamine
No inter-
vention
Unclear Unclear High High Unclear High Unclear Low
Macklon
1982
D-Peni-
cillamine
No inter-
vention
Unclear Unclear Unclear Unclear Low Low Unclear Low
Matloff
1982
D-Peni-
cillamine
No inter-
vention
Unclear Unclear Unclear Unclear Low Low High Low
Neu-
berger
1985
D-Peni-
cillamine
No inter-
vention
Unclear Low Low Low Unclear High Unclear Low
Taal 1983 D-Peni-
cillamine
No inter-
vention
Unclear Unclear Low Low Unclear Low Unclear Low
Triger
1980
D-Peni-
cillamine
No inter-
vention
Unclear Unclear Unclear Unclear Unclear High High Low
Mitchi-
son
1989
Gluco-
corticos-
teroids
No inter-
vention
Low Low High High Low High Unclear Low
Ueno
2005
Lamivu-
dine
No inter-
vention
Unclear Unclear Low Low Unclear High Unclear Low
Mitchi-
son
1993
Maloti-
late
No inter-
vention
Low Low Low Low High Low High Low
Hen-
drickse
1999
Methotrex-
ate
No inter-
vention
Low Low Unclear Unclear Unclear High Unclear Low
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Table 2. Risk of bias arranged according to comparisons (Continued)
Steenber-
gen
1994
Methotrex-
ate +
UDCA
No inter-
vention
Low Unclear Unclear Unclear Unclear High Unclear Low
Mayo
2015 NGM282
No inter-
vention
Unclear Unclear Unclear Unclear High High High Low
Bowlus
2014
Obeti-
cholic
acid
No inter-
vention
Unclear Unclear Unclear Unclear Unclear High High Low
Hirschfield
2015
Obeti-
cholic
acid
No inter-
vention
Low Unclear Low Low Low High Unclear High
Kowdley
2011
Obeti-
cholic
acid
No inter-
vention
Unclear Unclear Unclear Unclear Unclear High High Low
Manzillo
1993a
S-Adeno-
syl me-
thionine
No inter-
vention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Manzillo
1993b
S-Adeno-
syl me-
thionine
No inter-
vention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Cash
2013
Simvas-
tatin
No inter-
vention
Unclear Low High High High High Low High
Askari
2010 Tetrathiomolyb-
date
No inter-
vention
Low Low Low Low Low High Low High
Mc-
Cormick
1994
Thalido-
mide
No inter-
vention
Unclear Unclear Low Low Low High High Low
Arora
1990
UDCA No inter-
vention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Battezzati
1993
UDCA No inter-
vention
Low Low Low Low High High Unclear Low
Combes
1995a
UDCA No inter-
vention
Unclear Unclear Low Low Low High High Low
Eriksson
1997
UDCA No inter-
vention
Unclear Unclear Unclear Unclear High High High Low
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Table 2. Risk of bias arranged according to comparisons (Continued)
Heath-
cote
1994
UDCA No inter-
vention
Unclear Low Low Low Unclear High High Low
Leuschner
1989
UDCA No inter-
vention
Unclear Unclear Unclear Unclear High Low Unclear Low
Lim 1994 UDCA No inter-
vention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Lindor
1994
UDCA No inter-
vention
Unclear Unclear Low Low High Low High Low
Oka
1990
UDCA No inter-
vention
Unclear Low Low Low High High High Low
Pap-
atheodor-
idis
2002
UDCA No inter-
vention
Low Low High High High High High High
Pares
2000
UDCA No inter-
vention
Unclear Unclear Low Low Unclear Low High Low
Poupon
1991a
UDCA No inter-
vention
Unclear Unclear Low Low High High High Low
Senior
1991
UDCA No inter-
vention
Unclear Unclear Unclear Unclear High High High Low
Turner
1994
UDCA No inter-
vention
Unclear Unclear Low Low Low High Unclear Low
Goddard
1994
Interven-
tion 1:
UDCA
Interven-
tion 2:
colchicine
Interven-
tion 3:
colchicine
+ UDCA
No inter-
vention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Wolfha-
gen
1998
Azathio-
prine
+ gluco-
corticos-
teroids +
UDCA Low Low Low Low Unclear High High Low
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Table 2. Risk of bias arranged according to comparisons (Continued)
UDCA
Iwasaki
2008a
Bezafi-
brate
UDCA Unclear Low High High Unclear High Low Low
Kurihara
2000
Bezafi-
brate
UDCA Unclear Unclear Unclear Unclear Unclear High Unclear Low
Hoson-
uma
2015
Bezafi-
brate +
UDCA
UDCA Low Low High High Low Low Low Low
Iwasaki
2008b
Bezafi-
brate +
UDCA
UDCA Unclear Low High High Unclear High Low Low
Kanda
2003
Bezafi-
brate +
UDCA
UDCA Unclear Unclear Unclear Unclear Low High Unclear Low
Nakai
2000
Bezafi-
brate +
UDCA
UDCA Unclear Unclear Unclear Unclear Unclear High Low Low
Almasio
2000 Colchicine
+ UDCA
UDCA Low Low Low Low High High Low Low
Ikeda
1996 Colchicine
+ UDCA
UDCA Unclear Unclear Unclear Unclear Low High Unclear High
Poupon
1996 Colchicine
+ UDCA
UDCA Unclear Unclear Low Low Unclear Low High Low
Raedsch
1993 Colchicine
+ UDCA
UDCA Unclear Unclear Unclear Unclear High High Unclear Low
Yokomori
2001
Colesti-
lan +
UDCA
UDCA Unclear Unclear High High Unclear High Unclear Low
Liberopou-
los
2010
Fenofi-
brate +
UDCA
UDCA Unclear Unclear High High Unclear High Unclear Low
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Table 2. Risk of bias arranged according to comparisons (Continued)
Leuschner
1999
Gluco-
corticos-
teroids +
UDCA
UDCA Low Unclear Unclear Unclear High High High Low
Rauti-
ainen
2005
Gluco-
corticos-
teroids +
UDCA
UDCA Unclear Unclear High High High High High Low
Gao 2012 Gluco-
corticos-
teroids +
UDCA
Azathio-
prine +
UDCA
UDCA Unclear Unclear Unclear Unclear Unclear High Unclear Low
Mason
2008
Lamivu-
dine + zi-
dovudine
+ UDCA
UDCA Low Low Low Low Unclear High High Low
Combes
2005 Methotrex-
ate +
UDCA
UDCA Unclear Unclear Unclear Unclear Low High High Low
Gonza-
lezkoch
1997
Methotrex-
ate +
UDCA
UDCA Unclear Low Unclear Unclear Unclear Low Unclear Low
Nevens
2016
Obeti-
cholic
acid +
UDCA
UDCA Low Low Low Low High Low High Low
Ferri
1993
TUDCA UDCA Unclear Unclear Unclear Unclear Low High Unclear Low
Ma 2016 TUDCA UDCA Low Low Low Low Unclear High High Low
Kaplan
1999 Colchicine Methotrex-
ate
Unclear Unclear Low Low High High Unclear Low
Comparison of doses Comparison of doses
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Table 2. Risk of bias arranged according to comparisons (Continued)
Lindor
1997
Interven-
tion
1: UDCA
(high)
Interven-
tion
2: UDCA
(moder-
ate)
UDCA
(low)
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Angulo
1999a
Interven-
tion
1: UDCA
(high)
Interven-
tion
2: UDCA
(moder-
ate)
UDCA
(low)
Low Low Low Low Unclear Low Unclear Low
Van
Hoogstraten
1998
UDCA
(moder-
ate)
UDCA
(low)
Low Low High High Unclear High High Low
Maz-
zarella
2002
UDCA
(high)
UDCA
(moder-
ate)
Unclear Unclear Unclear Unclear Unclear High Unclear Low
TUDCA: taurodeoxycholic acid; UDCA: ursodeoxycholic acid.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• It was not possible to assess whether the potential effect modifiers were similar across different comparisons. Therefore, we did
not perform the network meta-analysis and assessed the comparative benefits and harms of different interventions using standard
Cochrane methodology. The methodology that we plan to use if we conduct a network meta-analysis in the future is available in
Appendix 1.
• We performed Trial Sequential Analysis in addition to conventional method of assessing the risk of random errors using P values.
N O T E S
There is considerable overlap between the ’Methods’ of this review and those of several other reviews written by the same group of
authors.
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